

The regulatory roles of phosphatases in cancer

Stebbing, J. , Lit, L. C. , Zhang, H. , Darrington, S. , Melaiu, O. , Rudraraju, B. and Giamas, G.

Author post-print (accepted) deposited in CURVE March 2016

Original citation & hyperlink:

Stebbing, J. , Lit, L. C. , Zhang, H. , Darrington, S. , Melaiu, O. , Rudraraju, B. and Giamas, G. (2014) The regulatory roles of phosphatases in cancer. *Oncogene*, volume 33 : 939-953
<http://dx.doi.org/10.1038/onc.2013.80>

DOI 10.1038/onc.2013.80

ISSN 0950-9232

ESSN 1476-5594

Publisher: Nature Publishing Group

Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.

This document is the author's post-print version, incorporating any revisions agreed during the peer-review process. Some differences between the published version and this version may remain and you are advised to consult the published version if you wish to cite from it.

The regulatory roles of phosphatases in cancer

Justin Stebbing^{*}, Lei Cheng Lit^{1*}, Siobhan Darrington, Ombretta Melaiu, Bharath Rudraraju, and Georgios Giamas[§]

Department of Surgery and Cancer, Division of Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK

* Equal contributors.

Keywords: Cancer, Phosphatases, solid tumours

[§]To whom correspondence should be addressed:

Dr Georgios Giamas
Department of Surgery & Cancer
Hammersmith Hospital Campus
Imperial College
Du Cane Road
London, W12 0NN, UK.
Tel: +442075942804
Email: g.giamas@imperial.ac.uk

Abstract

The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumor suppressor, across tumor types lends credence to the development of PI3-kinase inhibitors alongside use of the phosphatase's expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies.

A. Gastrointestinal malignancies

1. Esophageal cancer

Loss of *PTEN* expression in esophageal cancer is frequent, amongst other genes alterations characterizing this disease. Zhou *et al.* found that over-expression of *PTEN* suppresses growth and induces apoptosis in esophageal cancer cell lines, through down-regulation of *BCL2* resulting in changes in cell cycle progression. Moreover they have shown that *PTEN* gene therapy reduces tumour size *in vivo*, suggesting *PTEN* as an important biological marker (1). In addition, Hou *et al.* investigated the relationship of *PTEN* status and cell sensitivity to chemotherapeutic drugs *in vivo*. ESCC cells transfected with or without the wild type (wt) *PTEN* were inoculated subcutaneously into nude mice. Both wt *PTEN* and cisplatin could inhibit tumour growth and induce cell apoptosis. Cisplatin had the strongest inhibitory effects on tumours produced by cells transfected with wt *PTEN*, indicating that *PTEN* can increase the *in vivo* sensitivity of ESCC cells to cisplatin (2). As further evidence of the importance of *PTEN* in esophageal carcinogenesis, Juan Man *et al.* have recently found a strong association of genetic polymorphisms in *PTEN* with high risk of ESCC (3).

In another study, immunohistochemistry (IHC) of 100 patient's tumours with revealed that CDC25A and CDC25B phosphatases are strongly expressed in the cytoplasm of cancer cells (4). Furthermore, due to the role of CDC25B in cell growth, Dong *et al.* examined the levels of CDC25B antibodies (ab's) in sera from 134 esophageal squamous cell carcinoma patients and determined that they are higher compared to healthy subjects. Detection of CDC25B ab's in combination with traditional tumour markers (i.e. CEA, SCC-Ag, CYFRA21-1) resulted in an increased sensitivity of detection, with 64.2% of patients testing positive for at least one of these markers. Moreover, high levels of CDC25B ab's in sera were significantly associated with poor survival in advanced ESCC suggesting that they may have a clinical utility in ESCC screening and diagnosis (5).

Cao *et al.* investigated the role of *PTPN12* in ESCC and showed that *PTPN12* protein expression is higher in normal para-cancerous tissues than in 20 ESCC tissues. By performing IHC, high and low expression of *PTPN12* was found in 62.1% and 37.9% of ESCCs, respectively. Moreover they demonstrated that patients with completely resected ESCC and tumours with high *PTPN12* expression tumour had favorable survival compared to that of patients with low *PTPN12*, therefore proposing that *PTPN12* can be used as an independent predictor of patient survival (6).

Yan-Jie You *et al.* evaluated the methylation levels of protein tyrosine phosphatase receptor type O (*PTPRO*) promoter as a potential biomarker in ESCC. Their analysis revealed hypermethylated *PTPRO* promoter status in 27 (75%) out of 36 primary tumours. No methylated *PTPRO* was observed in normal peripheral blood samples from 10 healthy individuals. In addition, in *PTPRO*-silenced cell lines, expression was dramatically restored by

treatment with the demethylating agent 5-azadC, confirming that DNA methylation is a mechanism regulating *PTPRO* expression and that aberrant methylation of the *PTPRO* promoter is directly responsible for transcriptional inactivation of its expression in ESCC cell lines. These findings suggest that *PTPRO* is a common target for epigenetic silencing via methylation in ESCC, and that its methylation may be involved in esophageal cancer tumourigenesis (7). Moreover, Motiwala *et al.* examined the levels of *PTPRO* methylation in blood cells, since the presence of detectable methylated promoter DNA in blood cells has been reported to indicate the presence of circulating cancer cells during the process of distant metastasis. Interestingly, *PTPRO* methylation occurred only in B-cell population of a subset of patients with chronic lymphocytic leukemia (CLL), but not in normal B or T lymphocytes, indicating that methylated *PTPRO* in blood cells is cancer-specific (8). Finally, a high frequency of *PTPRO* hypermethylation in primary tumours significantly correlated with tumour stage, indicating that *PTPRO* methylation may be involved also in invasion of ESCC (7).

2. Gastric Cancer

Insertion of *cagA*-protein from *H. pylori* into the gastric epithelial cells specifically binds and activates PTPN11 oncoprotein (9, 10). Activated PTPN11 induces cell growth and motility (11), while deregulation of PTPN11 by *cagA* induces abnormal proliferation and migration of gastric epithelial cells that leads to gastric carcinogenesis (12). Several studies detected aberrant DNA methylation of *PTPN6* gene in gastric carcinomas. *H. pylori* infection led to a decrease in the methylation levels in *PTPN6* (13), inconsistent with a previous report (14). Yang *et al.* reported that *PTPN1* gene was amplified in gastric cancer tissues (15). With regards to the clinicopathologic characteristics, PTPN1 was associated with tumour metastasis and tumour-node-metastasis stage, implicating its involvement in the development of gastric cancer (16). As suggested, PTPN1 inhibitors may also be useful in the treatment of gastric cancer (17).

PTPN3 and *PTPN4* are two closely-related non-receptor tyrosine phosphatases that are expressed in human gastric cancer cells and tissue specimens (18). PTPN3 dephosphorylates and cooperates with p38 γ , to form a complex that may increase Ras oncogenesis through PDZ-mediated direct binding (19). The phosphatase activity of PTPN4 has been implicated in the regulation of cytoskeletal events (20). Overexpression of PTPN4 in COS-7 cells decreased colony formation, inhibited cell growth and decreased saturation density of these cells (21).

Wu and colleagues applied a RT-PCR-based protein-tyrosine phosphatase (PTP) profiling approach to study PTP expression in human gastric cancer samples, and identified sixteen PTPs in the cancer tissues; only six of them (PTPN4, PTPRB, PTPRH, PTPRJ, PRPRN and PTPRZ) were expressed in gastric cancer tissue (22), while PTPRA expression was significantly high in cancer tissues. The role of protein tyrosine phosphatase receptor type

A (PTPRA) in gastric cancer might be linked to its biological role in integrin signaling, cell adhesion and activating the SRC family tyrosine kinases (23-25). Reduced protein tyrosine phosphatase receptor type G (PTPRG) expression was detected by IHC in gastric tumour (22) indicating it might be a tumour suppressor gene. In addition, differences in DNA methylation of *PTPRG* genes between primary tumour and metastatic lymph nodes of gastric cancer was also observed (26). Until now, the detailed mechanisms underlying PTPRG-mediated cell signaling are undescribed.

In a mutational analysis study conducted by Wang *et al.*, protein tyrosine phosphatase receptor type T (*PTPRT*) was the most common mutated gene (27). Lee *et al.*, also detected a splice-site mutation in *PTPRT* gene in 1 of 48 gastric carcinomas and suggested that *PTPRT* phosphatase domain mutation may not play a role in the development of human cancers (28).

Finally, various reports have demonstrated over-expression of protein tyrosine phosphatase receptor type H (PTPRH) (29), DUSP1 (30) and phosphatase of regenerating liver (PRL-3) (31-35) in human gastric cancer, while Ooki *et al.*, (36) showed that PRL-3 genomic amplification was associated with advanced stage.

3. Colorectal Cancer

A systemic mutational analysis of the tyrosine phosphatome in human CRC has identified 83 somatic mutations in *PTPRF*, *PTPRG*, *PTPRT*, *PTPN3*, *PTPN13* and *PTPN14* genes (27). Similarly, frameshift mutations have been depicted in *PTPRA*, *PTPRS*, *PTPN5*, *PTPN13*, *PTPN21* and *PTPN23* (37), while hypermethylation of *PTPRO* was showing microsatellite instability colorectal tumours (38).

PTPN13 was shown to interact with the cytosolic domain of Fas (39), while Miyazaki *et al.* reported over-expression of PTPN13 enhances sensitivity to Fas-mediated apoptosis (40). However, Yao *et al.* demonstrated that expression of PTPN13 in more than 70% of colon cancers, was related to resistance against Fas-mediated apoptosis *in vivo* and *in vitro* (41). These contradictory reports reveal that PTPN13 may possess dual role in colon carcinoma, either as an oncogene or as a tumour suppressor depending on the cellular context in which it is studied.

Lassmann *et al.* evaluated distinct genomic DNA alterations using array comparative genomic hybridization and identified DNA amplification of *PTPN1* in 22% of the colorectal cancer cases, with the highest percentage in changes in chromosomal-positive tumours (42). *PTPN1* has been responsible for the activation and elevation of Src kinase activity in six human epithelial colon cancer cell lines (43).

Enhanced Src activity mediates signals and directs downstream activation of the JAK-STAT pathway. Signal transducer and activator of transcription 3 (STAT3) has been shown to be activated in colon tumours and cell lines (44, 45). Protein tyrosine phosphatase receptor-

type T (PTPRT) and protein tyrosine phosphatase receptor-type D (PTPRD) were shown to be able to regulate STAT3 (46, 47). As aforementioned, the mutation screen established that *PTPRT* was the most frequently mutated PTP in colorectal carcinomas. Zhang *et al.* demonstrated that PTPRT specifically regulates phosphorylation of STAT3-Tyr 705 in CRC (46). Over-expression of PTPRT activity inhibited cell growth, suggesting a tumour suppressor role (27). In addition, paxillin, a direct substrate of PTPRT, can be dephosphorylated at Tyr88 which is involved in cell-cell adhesion. Mutated PTPRT could promote CRC tumourigenesis and cell migration, while studies demonstrated the development of colon tumours in PTPRT knockout mice (48). It has been shown that *PTPRD* is frequently mutated in colon cancer (47, 49). Mutations in *PTPRD* abrogate the ability to regulate STAT3 and loss of *PTPRD* function promotes cancer progression (50).

The role of PTPRA in CRC is poorly understood. *PTPRA* mRNA levels were found to be increased 70% in late stage (Dukes' D) colorectal tumours compared to adjacent normal colon mucosa (51). Interestingly, over-expression of PTPRA increases substrate adhesion (25) and stromal invasion (52), while its silencing suppresses anchorage-independent growth and induces apoptosis in colon cancer cell lines (53).

PTPRH is also abundantly expressed in human CRC specimens (54) and CRC cell lines (29). In *PTPRH* deficient mice had normal intestinal tract, but loss of *PTPRH* inhibited tumourigenesis in mice with heterozygous mutation of the adenomatous polyposis coli gene, suggesting that *PTPRH* plays a role in promoting the intestinal tumourigenesis (55).

Another significant phosphatase that modulated JAK-STAT pathway is the low molecular weight protein tyrosine phosphatases (LMW-PTP). Malentacchi *et al.* observed an increase in the expression of *LMW-PTP* mRNA and protein level in colon tumour samples (56); clinically, overexpression of *LMW-PTP* is generally associated with a proliferative phenotype and poor prognosis (57). Here, over-expression of PRL-3 in primary colorectal tumour is associated with tumour aggressiveness (58, 59). Jiang *et al.* have shown that the loss of TGF β signaling leads to upregulation of PRL-3 expression and activation of the PI3K/PKB pathway (60), which can promote epithelial-mesenchymal transition (61). Further on, PTEN was down-regulated by PRL-3 as shown by protein expression and IHC (62-64).

Moreover, *DUSP1* is overexpressed in colon tumours (65); Montagut *et al.* suggested *DUSP1* as a potential biomarker of response to cetuximab in metastatic CRC patients (66).

Finally, Ruivenkamp and colleagues demonstrated that frequent deletion of the *PTPRJ* gene occurs in large percentage of sporadic colorectal tumours (67) and also found loss of heterozygosity at the *PRPRJ* locus in sample of human CRC (62).

4. Pancreatic Cancer

More than half of pancreatic ductal adenocarcinoma (PDAC) tissues exhibit increased PI3K and AKT expression (68-70). PH domain and Leucine rich repeat protein phosphatases (*PHLPP*) levels are markedly reduced in human PDAC that have elevated AKT phosphorylation (71). Studies have shown that *PHLPP1* and *PHLPP2* are able to terminate AKT signaling by directly dephosphorylating and inactivating AKT resulting in great suppression of tumour growth (72, 73).

Although *PTEN* mutations are rarely found in pancreatic cancer (74), it is important to note that *PTEN* loss of function may result in decreased sensitivity to apoptotic stimuli that could promote cellular over-growth and tumourigenesis (75-77). Chow *et al.* reported that TGF β reduces *PTEN* expression and enhances pancreatic cancer cells motility through calcium-dependent PKC α (78). They also demonstrated that TGF β down-regulates *PTEN* via activation of NF- κ B activity (79). Mutations and changes of expression levels of TGF β and *SMAD4* proteins could be observed in pancreatic cancer tissues (80-82). *SMAD4* is a tumour suppressor able to mediate signals from a family of TGF β ligands and via phosphorylation of receptor-activated *SMADs* (R- *SMADs*) proteins forming a trimeric complex. This complex translocates into the nucleus, binds to specific DNA sequence and activates gene transcription(83). Protein phosphatase, Mg²⁺/Mn²⁺ dependent, 1A (*PPM1A/PP2C α*) was identified as a phosphatase that dephosphorylates the SXS motif of R- *SMADs* and terminates TGF- β signaling (84).

Dual specificity protein phosphatase 6 (*DUSP6*) is a cytoplasmic dual specificity phosphatase that negatively regulates members of the mitogen-activated protein (MAP) kinase superfamily (MAPK/ERK, SAPK/JNK, p38), which are associated with cellular proliferation and differentiation (85). *DUSP6* dephosphorylates the active form of ERK2, which is constitutively expressed in pancreatic cancer cells (86). Moreover, *DUSP6* was reduced in invasive pancreatic carcinoma (86) and was missing in the majority of cultured pancreatic cancer cells (87, 88).

Finally, NF- κ B pathway has also been implicated in pancreatic cancer (89). Based on the classical NF- κ B pathway cascade, the phosphorylated IKK (I κ B kinase) can further phosphorylate I κ B, an inhibitory subunit of the NF- κ B that is proteolytically degraded upon phosphorylation (90). Protein phosphatase 2A (*PP2A*) is required for signal-dependent activation of IKK (91). Inhibition of *PP2A* triggers apoptosis in pancreatic cancer cell line through constant activation of the NF- κ B pathway (92). Li *et al.* ((93)) also suggested that treatment with cantharidin, selectively inhibits *PP2A* and suppresses the growth of PANC-1 cells when c-Jun N-terminal kinase pathway is over-activated.

B. Genito-urinary tumours

Renal cell and bladder cancer

Alkaline phosphatases (ALPL) are a group of tissue specific and tissue non-specific (TNAP) enzymes that have been previously implicated in suppressing meningiomas (94). However the relationship between ALPL levels and kidney cancer has not been established. The kidney expresses ALPL, which is used as a marker for organ function in patients' dialysis (95). High serum levels of ALPL have been associated with paraneoplastic syndrome, as observed in 77 out of 365 patients with stage II-IV renal cell carcinoma, decreasing the 5 year survival to 35.7% (96). ALPL is also used as a predictive marker for bone metastases, which is a common occurrence in patients with kidney and bladder cancer (97).

CDC25 phosphatases are frequently over-expressed in various malignancies, including RCC (98). In renal cancer cells, down-regulation of CDC25B induces a G2/M arrest and subsequent apoptosis with a concomitant reduction of the 14-3-3 protein. Furthermore, inhibition of the CDC25B reduces the rate of renal cell migration and invasion (99). Cpd5 is a selective inhibitor of CDC25 phosphatases, which acts as an anti-neoplastic agent for RCC. (100).

Serine/threonine-protein phosphatase PP1-alpha catalytic subunit (*PPP1CA*) is involved in pRb dephosphorylation and ceramide accumulation induced by RAS (101). Its role has been investigated in bladder cancer, as a potential marker for monitoring disease progression. Assessment of *PPP1CA* levels in urine was performed and correlated with standard cytology. Sensitivity of *PPP1CA* was 68.8% and the specificity was 62.7% ($p < 0.001$). A positive correlation was found between bladder cancer grade and sensitivity, while for grade 1 and grade 2 tumours, *PPP1CA* and other evaluated markers were even superior to cytology (102).

Protein tyrosine phosphatase, non-receptor type 21 (*PTPN21*) stimulates the Src-EGF signaling axis, and its involvement in actin cytoskeleton, cell adhesion and in regulating the stability and recycling of the EGFR has also been reported. *PTPN21* is required for growth and motility of urothelial cancer cells *in vitro*, and its high expression in human bladder cancer tissue correlates with advanced tumour stage and invasiveness. Therefore, *PTPN21* represents a novel biomarker and possible therapeutic target for bladder cancer. *PTPN21* over-expression is thought to be an early step in urothelial cancer progression. In terms of expression *in vivo*, *PTPN21* is absent from the normal bladder tissue, hyperplastic urothelium, and urothelial papilloma, whereas its expression gradually increases from low grade to high grade urothelial carcinoma (103).

In a study in clear cell RCC (ccRCC), which originates from proximal tubular tissue, microsatellite alternations at chromosome 9p23-22 (D9S168) were more common at late stage

renal cancer and associated with poor survival. The D9S168 alteration was associated with low expression of protein tyrosine phosphatase receptor delta (*PTPRD*), while IHC analysis revealed down-regulation of *PTPRD* expression in ccRCC, suggesting it as a potential tumour suppressor (104).

The *PTEN* gene is important for the growth suppression of RCC, by inhibiting cell proliferation. In renal carcinoma cell lines and primary RCC, the frequency of loss of flanking markers around *PTEN* is 20–43%, and somatic intragenic mutations are less frequent (<17%). However, the rate of *PTEN* inactivation at the protein level may be more frequent than that identified at the genetic level (105). A tissue microarray analysing 440 RCC specimens revealed that *PTEN* expression is typically decreased in RCC (106), and represents an early step in renal cell carcinogenesis. A negative correlation between pAKT and *PTEN* was found in primary RCC. In terms of cellular distribution, *PTEN* was weaker at the cytoplasmic level and stronger in the nucleus in RCC compared to normal renal parenchyma. Multivariate analyses revealed that altered expression of *PTEN* was associated with adverse patient outcome. (107). However, interestingly in patient samples with invasive muscular bladder cancer, *PTEN* was found to be located in the cell cytoplasm and a positive correlation between *PTEN* and pAKT was observed (108). In addition, lower *PTEN* expression was found in patients who died of metastases, within 5 years after surgery, compared to long-term survivors, indicating a critical role of *PTEN* in RCC progression. In particular, the pro-metastatic effects upon *PTEN* loss in RCC are achieved through Shc (109). *PTEN* attenuation also mediates resistance to cisplatin-induced apoptosis, through increasing levels of the cyclin kinase inhibitor p21 (110).

In primary bladder cancers loss of *PTEN* heterozygosity is seen in 23% of cases. Several portions of the gene were found deleted, namely that containing potential tyrosine and serine phosphorylation sites. Missense mutations in exon 1 and exon 2, that may inactivate the phosphatase activity of the *PTEN* gene were detected in bladder cancer cell lines derived from advanced stage bladder cancers, and were absent from a cell line derived from a lower stage cancer. However, *in vivo* analysis in 33 bladder cancer specimens, including the 25 T3/T4 bladder carcinomas, failed to replicate *in vitro* findings. Only 8% of the primary bladder cancer specimens are thought to harbor a mutation or homozygous deletion in *PTEN*, raising the possibility that another gene in close proximity to *PTEN* is the actual primary target of inactivation (111). In invasive bladder cancer, loss of *PTEN* in combination with altered p53 has adverse consequences and serves to identify a subgroup of patients with particularly aggressive disease, which are candidates for mTOR inhibitors as a therapeutic strategy (112). Finally, a recent mouse study found that *PTEN* deletion only influenced urothelial morphology when coupled with a deletion of LKB1 a tumour suppressor acting through TSC1 (113),.

Cyclin-dependent kinase-associated protein phosphatase (KAP) is expressed at the G1/S transition of the cell cycle and forms a complexes with cyclin-dependent kinase 2

(CDK2). KAP is over-expressed in renal cell carcinoma, while a correlation with higher histological grade has been shown (114). KAP promotes growth of RCC, and confers resistance to anti-TNF α induced apoptosis by preventing caspase-3 activation. Furthermore, HEK293 cells over-expressing KAP have a greater ability of cell invasion. *In vivo* xenograft models confirmed that KAP induces tumourigenicity with significantly larger xenograft tumours arising in nude mice inoculated with KAP over-expressing cells.

DUSP1 expression in renal cancer cells contributed to cell survival by attenuating the apoptosis inducing signal cascade via JNK. *DUSP1* is up-regulated at the mRNA and protein level in low-grade bladder cancers, and its expression is inversely proportional to tumour grade, suggesting its relevance in the early stages of bladder cancer development (115). *DUSP9* expression correlates with the onset of kidney carcinoma, where it is down-regulated at both the mRNA and at the protein level. Patients with tumours exhibiting low *DUSP9* expression had significantly worse overall survival, with *DUSP9* expression, having an independent predictive value (116).

HER-2 positive bladder cancers also exist and carry an adverse prognosis. Suppression of IFN- γ is often used as a therapeutic approach in bladder cancer patients. This treatment is probably less effective in HER-2 overexpressing/amplified tumours due to upregulated Src homology 2-containing PTPN11 signaling. A dysfunction in *PTPN11* regulation can cause abnormal cell growth and induce different kinds of cancers (117). *PTPN11* is mainly expressed in the collecting duct system and in distal tubules, and hardly in glomeruli and proximal tubules. Its abundance was evident in rare renal tumours such as chromophobe RCC or oncocytoma (118).

Finally, the inhibitor of apoptosis stimulatory protein phosphatase (iASPP) is a key inhibitor of p53. iASPP is important for bladder cancer cell proliferation (119), where it has been shown that iASPP knockdown inhibits cell growth and colony formation (120).

Prostate cancer

PTEN mutations were firstly identified in multiple advanced cancers including prostate cancer (PCa), leading to its potential role as a tumour suppressor gene (121, 122). Shortly, different groups confirmed that PTEN inactivation was frequently shown in prostate cell lines, xenografts as well as primary prostate cancer (123-126). Homozygous deletion of *PTEN* in the prostate epithelium resulted in malignant prostate carcinoma displaying its association with cancer progression (127). Biological function studies showed by dephosphorylation of PIP₃ to PIP₂, PTEN tumour suppressor acts as a vital negative regulator of the PI3K/AKT/mTOR pathways affecting many aspects of cellular activity including growth and survival, whereas loss of PTEN leads to activation of these signaling cascades (77, 128). In AKT-dependent mouse model, mTOR inhibition reserved prostate intraepithelial neoplasia (PIN) through the

modulation of apoptosis and HIF-1 related pathways (129). Inhibiting PDK1, which activates AKT and S6K, prevented the development of prostate adenocarcinoma induced by *PTEN* heterozygous in mice (130). It is now clear that tumours harboring *PTEN* loss are highly dependent on PI3K/AKT signal for survival and proliferation. Meanwhile, inhibition of these kinases can converse the effects of *PTEN* loss (131). Therefore, pharmacological targeting PI3K/AKT and mTOR kinases have provided potential therapeutic importance in *PTEN* null cancers, including PCa. Indeed, several molecules including PI3K inhibitor (XL147), AKT inhibitor (perifosine) and mTOR inhibitors (CCI-779 and RAD001) are under clinical development (132).

Furthermore, *PTEN* loss was shown to play an important role in the survival crosstalk between PI3K/AKT and androgen receptor (AR) in PCa progression. Upon acute androgen ablation in human PCa cell line LNCaP, *PTEN* inactivation displayed increased activity of the PI3K/AKT axis indicating a possible compensating phenomenon across PI3K/AKT and AR signaling (133, 134). Prostate cancers with *PTEN* null relapsed after androgen withdrawal and enjoyed the capability of growth in the absence of androgen. Moreover, global analysis of genomic alterations elicited by homozygous *PTEN* deletion identified genes associated with cancer metastasis (135). In addition, it has been reported that *PTEN* can suppress the transcriptional activity of AR and cell proliferation induced by androgen as well as prostate-specific antigen, whereas androgens prevented PCa cells from *PTEN*-dependent apoptosis in the presence of AR (136). Similar evidence described that *PTEN* can directly interact with AR resulting in an inhibition of the AR nuclear translocation and an increase of the AR degradation in a PI3K/AKT independent manner, while in *PTEN*-null context both AR expression and activity were elevated compared with wild-type MEFs (137). Collectively, *PTEN* loss may lead to a gain-of-function of AR in both PI3K/AKT dependent and independent environment. Coordinately, loss of *PTEN* and intensified AR may contribute to tumourigenesis and androgen refractory PCa.

Pro-apoptotic protein Par-4 was shown to be essential for *PTEN*-dependent apoptosis, while AKT can directly bind to Par-4 and inhibit its activity through phosphorylation resulting in the survival of prostate cancer cells (138). Recent studies demonstrated that Par-4 inactivation associates with *PTEN* loss in a high percentage of human prostate carcinomas. Similar to *PTEN*-heterozygous mice, Par-4-null mice only developed benign prostate lesions, whereas simultaneous Par-4 loss and *PTEN* haploinsufficiency caused invasive prostate cancer in mice through activating AKT signaling as well as NF-kappaB pathway (139).

PP1 and PP2A are two major classes of serine/threonine protein phosphatases involved in many different cellular processes, including survival, cell cycle and apoptosis through dephosphorylation of key regulators such as PKA, AKT, PKC and glycogen synthase kinase 3 (GSK3) (140, 141). PP2A comprises of several subunits: scaffolding, catalytic and regulatory. Each subunits of PP2A exists in at least two isoforms (142, 143). *PPP2CA* levels

were found decrease in majority of androgen-independent PCa cell lines and in cancer lesions as compared with the adjacent normal/benign tumour tissues (144). *PPP2R2A*, a potential tumour suppressor gene, was found commonly deleted among PCa with homozygous deletions and no significant association between common single nucleotide polymorphisms of *PPP2R2A* and sporadic prostate cancer. These findings suggested that it may play an important role in prostate cancer tumourigenesis on somatic levels (145). In PCa, caveolin-1 was shown to bind to and inhibit PP1 and PP2A resulting in AKT activity enhancement indicating an important interplay involving both two phosphatases in tumourigenesis (146). Recent studies showed that PP1 can regulate AR protein stability and cellular localization via dephosphorylation of Ser-650 (147). 2,4,3',5' tetramethoxystilbene (TMS), a synthetic trans-stilbene analog, was able to induce PP2A activation leading to inhibition of AKT. This in turn stimulated expression of cell cycle inhibitor p27(kip1) in PC-3 cells (148). A failed recruitment of PP2A-B α by TGF- β type I receptor was suggested to be partly responsible for TGF- β abundance in malignant prostate cells (149). Moreover, PP2A activity was decreased in androgen-independent PCa cells (C4-2) compared with androgen-dependent LNCaP cells, whereas inhibition of PP2A enabled LNCaP cells to grow in an androgen-deprived condition (150). Sodium selenate, a specific selenium-containing compound, was identified as PP2A activator which significantly augmented the activity of PP2A, thereby inhibiting VEGF-induced growth and vessel branching of endothelial cells, and obstructing tumour neovascularisation. This anti-angiogenesis effect via PP2A allowed it into a phase I study in patients with castration-resistant PCa and results showed a similar effect to other anti-angiogenic agents (151, 152).

The cell division cycle 25 (CDC25) families are dual specificity phosphatases functioning in activation of cyclin-dependent kinases (CDK), which in turn modulate cell cycle progression. In mammalian cells, three isoforms have been identified: CDC25A, CDC25B and CDC25C (153). CDC25A and CDC25B were shown to be overexpressed in human PCa tissues and high Cdc25B associated with high Gleason scores and aggressiveness in PCa (154, 155). These two different studies also demonstrated that CDC25A can suppress androgen-responsive promoter via physically interaction with AR, whereas CDC25B can function as a coactivator of AR in a hormone-dependent manner in LNCaP. Similarly, CDC25C expression was elevated in PCa in comparison with normal prostate tissues and its spliced isoform was also found to be correlated with increased growth in PCa (156). Theaflavin (TF), a black tea polyphenol, can cause G2/M phase arrest in PC-cells by inducing cyclin kinase inhibitor p21 (waf1/cip1) and inhibiting CDC25C and cyclin B (157). Taken together, several studies have shown that CDC25 family phosphatases are important players in PCa progression and may provide potential therapeutic targets in PCa.

SHP1, an SH2 domain-containing protein tyrosine phosphatase, was detected in normal prostate, benign prostate hyperplasia, prostate epithelial cells and well differentiated adenocarcinoma, whereas diminished SHP1 expression was observed in malignant prostate

tissue and poorly differentiated advanced prostate cancer (158-161). Moreover, SHP1 overexpression decreased PC-3 cell proliferation (159). Tassidis *et al.* demonstrated the expression of SHP1 mRNA and protein in two human prostate cancer cell lines, LNCaP and PC-3, were at different levels (161). In this study, silencing SHP1 in LNCaP, which expresses high amount of endogenous SHP1 protein, exhibited an increase in cellular proliferation and cyclin D1. In contrast, in PC-3 cells, with low endogenous level of SHP-1 expression, overexpression of SHP-1 resulted in a decrease in proliferation and cyclin D1. A recent study showed that depletion of SHP1 in PC-3 cells caused G1 phase cell-cycle arrest by increasing p27 protein stability, due to its capability of regulating PI3K/AKT pathway and cyclin-dependent kinase 2 (CDK2) activity. This indicated that SHP1 may play a role in the regulation of cell cycle progression (162).

SHP2, an SH2 domain-containing protein tyrosine phosphatase sharing homology with SHP-1, is also expressed in prostate cancer cell lines including PC-3, DU145, LNCaP and LNCaP-IL6+ as well as patient specimens with PCa. SHP2 staining from 122 patients showed that low cytoplasm intensity associated inversely with prostate volume while staining in the nuclear was positively correlated with extracapsular extension. This implicated that SHP-2 ablation in the cytoplasm correlated with enhanced tumour growth (163). However, other studies reported that SHP2 may act as a proto-oncogene product by increasing Ras-MAPK signaling (164).

C. Gynaecologic tumours

1. Endometrial cancer

There are two main types of endometrial cancer (EC) namely type-I, which is estrogen receptor and progesterone receptor positive with low grade and type-II with clear-cell or serous morphology and high grade (165), (166, 167). Currently, endocrine and chemotherapy are being used to treat type-I EC (168). Although most clinical trials and treatment regimens do not stratify patients according to type, research at molecular level have identified distinct genetic alterations and signaling pathways between the two types. For example, type I cancer frequently has deregulated PI3K/PTEN/AKT pathway and loss of PTEN function while type-II has alterations in P53 and /or P16 pathways along with over expression and amplification of HER2.

PP2A is a well-known tumour suppressor which inhibits RAF-MEK-ERK pathway by inhibiting activity of ERK and RAF besides inhibiting the downstream signaling of RAS pathway via de-phosphorylation and inhibition of c-Myc, RALA and AKT. Depending on the type of cancer, this function of PP2A has been shown to be mediated by regulatory β subunits (169). On the contrary, somatic missense mutations in PPP2R1A, which encodes the α -isoform of the PP2A scaffolding subunit, were demonstrated in high-grade serous endometrial tumours (170).

Constitutive activation of MAPK pathway is known to play an important role in EC and since DUSP6 can negatively regulate ERK2, Chiappinelli *et al.* studied its methylation status in EC. They identified that silencing of DUSP6 is uncommon and unlikely to cause activation of MAPK pathway in EC (171). On the other hand, LMW-PTP, was studied and a significant association was identified in low grade EC with genotypes carrying the *C allele along with high concentration of S isoform (172).

Finally, Jay *et al.* studied the role of phosphatases in determining racial inequality in EC. Using microarray they identified phosphoserine phosphatase (*PSPH*), which is essential for the synthesis of L-serine, and designated phosphor-serine phosphatase like (*PSPHL*) as the most over-expressed genes in EC in African-Americans when compared to Caucasians (173).

2. Cervical cancer

The role of Protein phosphatase 1 (PP1) in tumour metastasis was studied by knockdown of PP1 and its regulator NIPP1 in HeLa cells. Knockdown of PP1 prevented migration of HeLa cells by inhibiting Cdc42 signaling pathway (174). Zeng *et al.* identified Protein phosphatase 1 inhibitor 5 (IPP5) as a tumour suppressor in cervical cancer; over-expression of mutant IPP5 in HeLa cells, caused G2/M arrest both *in vitro* and *in vivo* via inhibition of ERK activation (175). Furthermore, Protein phosphatase 1, regulatory subunit 7 (PPP1R7) was shown to be significantly up-regulated in metastatic CC patient samples after radiotherapy (176). Moreover, hSHIP, a human SH2-containing inositol-5-phosphatase, has also been shown to inhibit growth and act as a tumour suppressor in CC. *In vitro* and *in vivo* studies by He *et al.* have shown that stable over expression of hSHIP induces S-Phase arrest along with down regulation of AKT1/2 expression and phosphorylation, thereby inhibiting proliferation of cervical cancer HeLa cells (177). Taken together, PP1 and its regulatory subunits along with hSHIP, play an important role in progression and therapeutic response in CC and can prove to be new therapeutic targets.

Dual specificity phosphatase 3 (*DUSP3*) is known to dephosphorylate ERK1/2 and JNK1/2 MAPK kinases, which are key regulators of cellular differentiation, proliferation and apoptosis. In CC, knockdown of *DUSP3* inhibited the growth of HeLa cervical cancer cells by increasing the expression of cyclin dependent kinase inhibitor, p21 and inhibiting G1-S and G2-M cell cycle transition (178). This *in vitro* study was further supported by detection of increased expression and nuclear localization of *DUSP3* in cervix cancer cell lines when compared to normal keratinocytes as well as in HPV positive cell lines when compared to HPV negative cell lines. Furthermore, increased expression was identified in primary cervix cancer biopsies, including squamous cell carcinomas of uterine cervix and squamous intra epithelial lesions indicating potential use of *DUSP3* as a new marker for progression of CC and as a new target for anticancer therapy (179). Small-molecule inhibitors for *DUSP3* have been developed

which can inhibit enzymatic activity of DUSP3 at nanomolar concentrations while inhibiting the proliferation of cervix cancer cell lines without affecting proliferation of primary normal keratinocytes (180).

PP2B or serine/threonine phosphatase calcineurin (CaN) was shown to promote CC cell proliferation by directly interacting and enhancing c-Jun protein stability and activity. This was confirmed in cervical tissue samples that showed decreased phosphorylation of c-Jun and enhanced PP2B and c-Jun expression (181). In contrast, PP2B was shown to be down-regulated in malignant squamous carcinomas (182). This inconsistency might be due to the small number of samples used in both the studies and requires further investigation. On the other hand, no mutations were identified in *PPP2R1B* gene which encodes the beta isoforms of the subunit A of the PP2A between normal and cancer (183).

Expression of SHP-2 tyrosine phosphatase, was negatively associated with IFN- β expression in CC while its silencing inhibited growth of SiHa CC cell line by inducing expression of IFN- β , (184). Other phosphatases that can either inhibit or promote CC include hSHIP, a human SH2-containing inositol-5-phosphatase and DUSP-3 respectively (177, 179, 180).

Cancerous inhibitor of protein phosphatase 2A (CIP2A) was shown to be over expressed in CC when compared to normal tissue by IHC and RT-PCR. More importantly, papillomavirus 16 E7 oncoprotein directly upregulated CIP2A expression which could enhance proliferation and growth of CC cells by modulating c-Myc expression (185).

Finally, mutation and loss of PTEN has also been shown to drive tumourigenesis here (186, 187), as previously described.

3. Ovarian cancer

Inactivation of PTEN, by genetic mutation is well-known in ovarian cancer (OC) (188). Several *in vitro* studies have shown that PTEN can regulate growth, invasion, migration and resistance to chemotherapy in OC (189-193). Interestingly, PP2A has been shown to regulate PTEN; inhibition of PP2A decreased the expression of PTEN and enhanced phosphorylation of PTEN and AKT, causing increased migration/invasion of OC in fibrillar collagen, indicating PP2A as a tumour suppressor in OC. This was further supported by detection of decreased expression and activity of PP2A in OC tissue (194).

Expression of CIP2A, studied in 562 serous ovarian cancer patients by IHC, showed strong cytoplasmic staining in 40% of the samples and was associated with high grade, advanced stage and poor outcome (195). On the other hand, inhibition of PP2A was essential for the apoptosis induced by doxorubicin (196) and translocation of PP2A to plasma membrane was essential for gonadotropin-releasing hormone (GnRH) antagonist, cetrorelix induced apoptosis in GnRH responsive ovarian cancer cells (197).

A study by Manzano *et al.* evaluating the expression of 68 phosphatases in ovarian epithelial and cancer cell lines identified a 10-25 fold higher expression of DUSP1 in normal compared to malignant OC cell lines. This was confirmed by IHC staining in normal and OC specimens and was shown to be a critical factor in the progression of cancer (198).

PTPN13as found to be increased both at RNA and protein level in Fas resistant OC cell lines as well as in OC patient samples studied using tissue microarray (199). Knockdown of PTPN13 using siRNA enhanced the sensitivity of SKOV3 cells to carboplatin indicating that it can play a key role in carboplatin resistance (200).

In 106 OC patient samples, cell cycle related phosphatases, CDC25A and CDC25B were found to be commonly expressed and were associated with poor prognosis independent of tumour grade, histotype, stage and residual tumour after surgery, thereby, indicating potential role of these phosphatases to be used as prognostic factors (201).

Using northern blots and immunoblotting, Mok *et al.* have shown that PTPN6 was over expressed in 7 of the 8 ovarian epithelial carcinoma cell lines both at RNA and protein level along with over-expression in invasive ovarian epithelial cancer tissues (202).

Cisplatin is one of the most widely used drugs for treating OC. Sensitivity to Cisplatin is known to be partly mediated by activation of p53 by checkpoint kinase 1 (CHK1). Protein phosphatase magnesium-dependent 1 (PPMD1) is known to deactivate p53 and Chk1 via dephosphorylation. Using cisplatin resistant cell lines, Ali *et al.* showed knockdown of PPMD1 can re-sensitize resistant cells to cisplatin by activating P53 and CHK1 (203). Moreover, PPM1D was shown to be highly expressed at mRNA level in ovarian clear cell carcinoma cell lines with amplification at 17q23.2 and was amplified in 10% of primary clear cell carcinomas (204). The role of protein phosphatases in cisplatin sensitivity was also studied by Bansal *et al.* and they identified that patients with incomplete response to cisplatin had two-fold lower PP2C levels when compared to those with complete response. This was confirmed by western blotting in platinum-resistant OC cells (205). Moreover, genome-wide expression profiling of SK-OV-3 ovarian cancer cells identified two regulatory subunits of PP2A as key mediators of sensitivity to cisplatin and knockdown of each subunit by RNA interference made OC cells more responsive to cisplatin (206).

Polato *et al.* studied the role of PRL-3 in OC and expression of PRL-3 mRNA was found to be higher in stage III OC samples when compared to stage I samples and by using siRNA, PRL-3 was shown to be important for growth of OC cells *in vitro* (207, 208). Moreover, PRL-3 regulated migration and invasion of OC cells by interacting with integrin α 1, inhibiting phosphorylation of integrin β 1 and enhancing the downstream phosphorylation of Erk1/2(209). *In vivo* mice studies have shown that monoclonal antibodies against PRL-3 can prevent both tumour growth and metastasis of ovarian cancer cells making it a potential target for therapy in OC (210).

Finally, Tanyi *et al.* identified decreased mRNA expression of phosphatidic acid phosphatase type 2A (PPAP2A, LPP-1) in OC, which is known to degrade lysophosphatidic acid that can promote tumour growth and metastasis (211).

D. Other tumours

Lung cancer

Several phosphatase (PTPases) have been identified to play a role in this malignancy. Omerovic J. *et al.* performed a phosphatome RNAi screen in A549 lung cancer cells and ranked their effects on phosphorylation of AKT-Ser473. Although, phosphatase and tensin homolog (*PTEN*) appeared to be the main factor involved in inhibiting the oncogenic *K-Ras*, other phosphatases have been identified with similar potencies including protein tyrosine phosphatase non-receptor type 2 (*PTPN2*) and protein tyrosine phosphatase non-receptor type J (*PTPRJ*) (212). *PTEN* protein expression was reduced or lost in 74% of lung tumours, with loss occurring more often in well to moderately differentiated tumours. In NSCLC, loss of *PTEN* protein expression occurs frequently, although the mechanism responsible for loss is not clearly attributable to deletion or epigenetic silencing. *PTEN* loss may also be a favorable prognostic marker, although further studies are needed to confirm this finding (213). Scrima *et al.*, have suggested protein tyrosine phosphatase non-receptor type 13 (*PTPN13*) as candidate tumour suppressor gene in NSCLC. This gene is frequently inactivated in NSCLC through somatic mutation (approximately 8%) or due to loss of protein expression (approximately 73%); *PTPN13* negatively regulates anchorage-dependent and anchorage-independent growth of NSCLC cell lines *in vitro* (214).

The CDC25 phosphatases are known to play an important role in cancer cell growth. Increased expression of cell division cycle 25 homolog B (*CDC25B*) has been reported in tumours of different tissue origins, including NSCLC. Analysis of primary tumours and corresponding healthy lung tissues from 177 patients with NSCLC revealed an over-expression of *CDC25B* in 45.76% of the samples. Moreover, high expression of *CDC25B* correlated with positive expression of endothelin-, and with the number of intratumoural microvessels. Statistical analysis of survival data revealed that elevated *CDC25B* expression was significantly associated with shorter disease-free and overall survival, suggesting that *CDC25B* might play an important role in the angiogenic process and in determining the prognosis of patients with NSCLC (215).

Another protein known to play a role here is the dual specificity phosphatase 1 (*DUSP1*). It has been shown that down-regulation of *DUSP1* induced changes in the expression levels of genes involved in specific biological pathways, including angiogenesis,

MAP kinase phosphatase activity, cell–cell signaling, growth factor and tyrosine-kinase receptor activity. Changes in the expression of some of these genes were due to modulation of c-Jun-N-terminal kinase and/or p38 activity by *DUSP1*. Another report showed that silencing of *DUSP1* inhibits invasion and metastasis in NSCLC tumour (216).

Moreover, Chitale *et al.* examined 199 lung adenocarcinomas by integrating genome-wide data on copy number alterations and gene expression and revealed that non-random patterns of copy number alterations are linked to *EGFR* and *KRAS* mutation status. They also discovered a striking association of *EGFR* mutations with under-expression of dual specificity phosphatase 4 (*DUSP4*), which is involved in negative feedback control of *EGFR* signaling. Clinically, *DUSP4* loss has a significant impact on overall survival, further supporting its biological significance in lung adenocarcinomas.

DUSP4 loss also associates with *p16/CDKN2A* deletion and defines a distinct clinical subset of lung cancer patients (217).

Another phosphatase that seems to play a role in tumourigenesis is the protein tyrosine phosphatase non-receptor type 12 (*PTPN12*), by regulating cell adhesion and migration. However, the mechanism by which *PTPN12* is regulated in response to oncogenic signaling is unclear. Zheng *et al.*, have shown that *Ras* induces extracellular signal-regulated kinase 1 and 2 (ERK1/2)-dependent phosphorylation of *PTPN12* at Ser-571, which recruits peptidylprolyl cis/trans isomerase, NIMA-interacting 1 (PIN1) to bind to *PTPN12*. Isomerization of the phosphorylated *PTPN12* by PIN1 increases the interaction between *PTPN12* and focal adhesion kinase (FAK, PTK2) which leads to dephosphorylation of FAK-Tyr397 and the promotion of migration, invasion, and metastasis of v-H-Ras-transformed cells (218).

Breast Cancer

Up-regulation of *PTPN1* was first described in human BC cell lines over-expressing the *neu* oncogene (219). Wiener *et al.* reported a correlation between increased expression of *PTPN1* and HER2 expression human mammary tumours compared with normal breast tissue (220). Global deletion of *PTPN1* either delayed or protected against mammary cancer in mice, depending on the HER2/Neu allele and mice strain used (221, 222), suggesting that inhibition of *PTPN1* may be a potential target for treating breast cancer. Targeted *PTPN1* silencing in the mammary epithelium of either established mouse tumours, or in human BC cells xenografts grown on HER2 positive mice has been shown to delay the early onset of formation of mammary tumours (223).

Recent studies indicate that *PTPN13* may be effective therapeutic target for the treatment of breast cancer. Lower levels of *PTPN13* have been described in BC and metastatic tissue specimens (224) and increased expression of *PTPN13* is associated with a favorable outcome in BC patients (225). Over-expression of *PTPN13* is sufficient to block the

IRS-1/PI3K/MAPK pathway (226). In addition, over-expression of PTPN13 in combination with anti-estrogen treatment increased apoptotic cell death by the reduction of IGF-1 induced IRS-1 and AKT phosphorylation (227). PTPN13 can also inhibit tumour aggressiveness via the direct dephosphorylation of Src at Y419 (224), which is upregulated in tamoxifen resistance ER-positive breast cancer patients (228). New therapeutic routes using tamoxifen and SRC inhibitors are currently being examined (229, 230).

Loss of functional PTEN has been described in primary and metastatic breast tumours (231, 232) resulting in hyperactivation of the PI3K pathway and an increase in cell proliferation (233). Down-regulation of PTEN activity and activation of the PI3K signaling pathway is associated with resistance to anti-estrogen therapy (234). Screening for PTEN mutations may identify BC patients who may benefit from treatment with AKT inhibitors. In this regard, BC cell lines with PTEN mutations were recently described to have increased sensitivity to the novel AKT inhibitor MK-2206 (235).

Several other PTP's have a tumour suppressor function in BC. PTPN12, has been shown to act as a potent tumour suppressor in triple negative breast cancer cells and is more frequently inactivated in this BC subtype. Genetically silencing *PTPN12* induces transformation and disrupts acinar formation in mammary epithelial cells (236). Levels of cytoplasmic protein tyrosine phosphatase non-receptor type 9 (PTPN9) inversely correlate with STAT3 in BC tissue (237). PTPN9 has been reported to inactivate STAT3 following EGFR dephosphorylation in breast cancer cells (238), suggesting that PTPN9 may play a critical role in BC development.

A number of DUSPs are dysregulated in BC. The majority of breast carcinomas, including both poorly differentiated and metastatic stages disease, express higher levels of DUSP1 compared to normal breast tissue (65, 239). Studies suggest that inhibition of DUSP1 may be an effective therapeutic target against chemoresistance in BC patients. Increased expression of DUSP1 has been shown to correlate with decreased JNK activity (239). Overexpression of DUSP1 in BC cell lines treated with chemotherapeutic agents, which target the JNK pathway, protects against apoptosis. Conversely, genetic or chemical silencing of DUSP1 enhances sensitivity to chemotherapeutics agents (240), indicating that combination therapies that target this enzyme may be effective in the treatment of BC.

DUSP3, DUSP4 and DUSP5 also negatively regulate ERK signaling. DUSP4 up-regulation has been described in BC tumours (239). Deficiency of DUSP4 has been identified as a mechanism of neoadjuvant drug chemoresistance in breast cancer tumours. DUSP4 depletion is frequently found in chemotherapy refractory tumours which are associated with increased cell proliferation and basal-like BC status. Over-expression of DUSP4 either in breast cancer cell lines or in BC xenograft mouse models increased chemotherapy-induced apoptosis, whereas depletion reduced chemosensitivity (241). Upregulation of DUSP3 and DUSP5 has been reported in PMA-treated MCF-7 and BKBR3 breast cancer cell lines. Activation of the

ERK1/2 pathway and accelerated growth arrest of BC cells, has been observed following silencing of either DUSP3 or DUSP5, and overexpression of either phosphatase prevents growth inhibition and cell migration (242).

The novel phosphatase, VHZ (VH1-like (member Z)), encoded by the DUSP23 gene, is also associated with BC and has been identified in some invasive ductal and epithelia BC tumours. VHZ has been shown to localise to the centrosome and enhance G₁/S cell cycle progression, suggesting that this enzyme may be a potential chemotherapeutic target (243).

All three CDC25 isoforms (CDC25A, CDC25B, CDC25C) can regulate G₁/S and G₂/M cell cycle transition (153). CDC25A overexpression is associated with poor survival in BC patients (244-246). In addition, CDC25A 263C/T and -51C/G polymorphisms gene polymorphisms are associated with BC incidence and metastatic potential have been identified in BC patients, suggesting that CDC25A gene may be candidate markers for earlier diagnosis and targets for BC therapy (247). Recent studies have demonstrated increased Fox1 activity following CDC25A-induced dephosphorylation of CDK2. Inhibition of CDC25A inhibits metastases in BC mouse models, suggesting that this phosphatase may be a potential target for advanced stages of the disease (248). CDC25B is overexpressed in primary BC tumours (249), although expression levels do not always correlate with an aggressive phenotype (250). CDC25C splice variants have been found to shift or be elevated in BC cell lines, particularly in cell lines with multi-drug resistance or those treated with sub-lethal levels of genotoxic agents (251, 252), suggesting that CDC25C splicing may be an additional regulatory event involved in cellular response to DNA damage in BC cells.

The oncogene SRC3, which is overexpressed or amplified in the majority of breast cancer tumours (253), is a target for PP1. PP1 can block proteasome-dependent turnover of SRC-3 by dephosphorylation at Ser-101 and Ser-103, resulting in the stabilisation of SRC-3 (254). Increased expression of mutated PP2A at the active phosphatase site pY307 has been reported in HER2/neu BC tumours, which significantly correlated with disease progression (255). Loss of PP2A activity in HER2/neu positive BC cells resulted in apoptotic cell death mediated by p38 MAPK caspase-3 PARP activation (256), suggesting that this phosphatase may be a potential therapeutic target in BC.

MCF7 cells carry an amplified PPM1D/Wip-1 gene and overexpress PPM1D phosphatase protein. Silencing PPM1D has been reported to enhance doxorubicin-induced apoptosis due to p53-mediated phosphorylation of Bax (257).

Over-expression of the Eyes Absent (EYA) family of proteins, which are essential co-activators of the Six1 family of homeobox transcription factors, have recently been reported to enhance the proliferation, migration and invasiveness of BC cells (258). Silencing of EYA2 in MCF7 cells reverses the ability of Six1 to induce TGF- β signaling and induce characteristics associated with epithelial-mesenchymal transition (259). High-throughput screening assays have recently identified a series of specific small molecule EYA2 phosphatase inhibitors that

may be useful for the development of future BC therapies (260).

Sarcomas

Sarcomas are probably even more heterogenous than all the aforementioned tumour types (261).

PP2A has been identified in a protein array screen for interacting proteins with the Kaposi's sarcoma-associated herpesvirus (KSHV) LANA protein, which functions in latently infected cells as an essential component of KSHV replication and dysregulated cell growth. The subunits PP2A and PP2B, but not the catalytic subunit PP2C, were found to associate with LANA, suggesting that PP2A activity may be dysregulated in this sarcoma (262).

Alterations in PTEN expression have been described in several types of sarcoma. PTEN up-regulation has been described in 80% of tissue samples from Kaposi's Sarcoma biopsies, with 58% having expressing phosphorylated PTEN (263). PTEN losses and mutations are also a frequent occurrence in the malignant smooth muscle neoplasm, leiomyosarcoma (264-266).

SHP2 may be a promising therapeutic target for Kaposi's sarcoma. Constitutive activation of the vGPC receptor, the Kaposi's herpes sarcoma virus associated chemokine has been shown to result in the phosphorylation of SHP2 (267). The vGPCR contains a bona fide immunoreceptor tyrosine-based inhibitory motif (ITIM) that binds and constitutively activates Shp2 (268). Moreover, SHP2 is required for vGPCR activation of the MEK-ERK1/2 axis, the transcription factors AP-1 and NFκB and vGPCR-induced endothelial cell migration (267).

PTPN13 is highly expressed in Ewing's Sarcoma family tumours (ESFT) cell lines and in patient tumours, with higher expression levels in metastatic compared to primary tumours. PTPN13 has been found to associate with the aberrant transcription factor EWS-11, and is up-regulated following overexpression of EWS-11(269). MK-STYX, which encodes for a MAP-kinase phosphatase-like protein, is also constitutively expressed in EFST and may be a putative target for therapy in this class of tumours (270).

Conclusions

Phosphatases, like kinases, represent molecular switches that can turn on or off a variety of signaling pathways (**Fig 1**) resulting in abnormal cellular processes including uncontrolled proliferation, differentiation, angiogenesis and metastasis. Thus far, a large number of phosphatases has been associated with the development and progression of different types of cancer (**Table 1**). Further understanding and clarifying the involvement and role of phosphatases in signal transduction would be very helpful in developing new effective drugs to be used alone or in combination with other therapeutics for cancer treatment.

Acknowledgement

We would like to thank Aleksandra Filipovic for helping editing the manuscript. J.S. and G.G. are supported by grants from the National Institutes of Health Research, Imperial Biomedical Research Centre and Experimental Cancer Medicine Centre and Cancer Research UK.

Conflict of interest

The authors declare no conflict of interest.

Table Alterations observed in phosphatases and resulting malignancies.

Gene symbol	Uniport KB	Expression
PTEN	P60484	lung(213), esophageal(1-3), pancreatic(74), kidney(106), bladder(111), cervical(186, 187), ovarian(188), breast(231, 232), sarcoma(263), prostate(123-126)
PTPN1	P18031	gastric(15, 271), colorectal(42), breast(219)
PTPN2	P17706	lung(212)
PTPN3	P26045	gastric(18), colorectal(27)
PTPN4	P29074	gastric(18, 22)
PTPN6	P29350	gastric(13), ovarian(202), prostate(158-161)
PTPN9	P43378	breast(237)
PTPN10	P28562	lung(216), gastric(30), colorectal(66, 272), bladder(115), ovarian(198), breast(239, 272)
PTPN11	Q06124	gastric(9, 10), kidney(118), cervical(184), sarcoma(267), prostate(163)
PTPN12	Q05209	lung(218), esophageal(6), breast(236)
PTPN13	Q12923	lung(214), colorectal(27, 41), ovarian(199), breast(225), sarcoma(269)
PTPN14	Q15678	colorectal(27)
PTPN21	Q16825	bladder(103)
PTPN23	Q9H3S7	colorectal(27)
CDC25A	P30304	esophageal(4), ovarian(201), breast(244-246), prostate(155)
CDC25B	P30305	lung(215), esophageal(4), kidney(99), ovarian(201), breast(249), prostate(154)
CDC25C	P30307	breast(251, 252), prostate(156)
DUSP3	P51452	cervical(179), breast(242)
DUSP4	Q13115	lung(217), breast(239, 241)
DUSP5	Q16690	breast(242)
DUSP6	Q16828	pancreatic(86-88), endometrial(171)
DUSP23	Q9BVJ7	breast(243)
PTPRA	P18433	gastric(22, 26), colorectal(51, 53)
PTPRB	P23467	gastric(22)
PTPRD	P23468	colorectal(47, 49), kidney(104)
PTPRF	P10586	colorectal(27)
PTPRH	Q9HD43	gastric(22, 29), colorectal(29, 54, 55)
PTPRJ	Q12913	lung(212), gastric(22), colorectal(62, 67)
PTPRG		colorectal(27)
PTPRN	Q16849	gastric(22)
PTPRO	Q16827	esophageal(7), colorectal(27)
PTPRT	Q14522	gastric(28), colorectal(27, 46, 48)
PTPRZ	P23471	gastric(22)
PTP4A3	Q75365	gastric(31-36), colorectal(58, 59), ovarian(207, 208)
LMW-PTP	P24666	colorectal(56)
PHLPP1	Q60346	pancreatic(71)
PPP1CA	P62136	
PPP1CB	P62140	bladder(102), cervical(174), prostate(146, 147)
PPP1CC	P36873	
PPP2CA	P67775	pancreatic(92, 93), cervical(182), endometrial(170), ovarian(194),
PPP2R2A	P63151	breast(255), sarcoma(262), prostate(144-146)
PPP2R1B	P30154	
PPM1D	Q15297	ovarian(204), breast(257)
ALPL	P05186	kidney(97), bladder(97)
CDKN3	Q16667	kidney(114)
PSPH	P78330	endometrial(173)
PPAP2A	Q14494	ovarian(211)
EYA2	Q00167	breast(258)

References

1. Zhou YA, Zhang T, Zhao JB, Wang XP, Jiang T, Gu ZP, et al. The adenovirus-mediated transfer of PTEN inhibits the growth of esophageal cancer cells in vitro and in vivo. *Biosci Biotechnol Biochem.* 2010;74(4):736-40. PubMed PMID: 20378992. Epub 2010/04/10. eng.
2. Hou G, Lu Z, Liu M, Liu H, Xue L. Mutational analysis of the PTEN gene and its effects in esophageal squamous cell carcinoma. *Dig Dis Sci.* 2011 May;56(5):1315-22. PubMed PMID: 21116717. Epub 2010/12/01. eng.
3. Ma J, Zhang J, Ning T, Chen Z, Xu C. Association of genetic polymorphisms in MDM2, PTEN and P53 with risk of esophageal squamous cell carcinoma. *J Hum Genet.* 2012 Apr;57(4):261-4. PubMed PMID: 22336889. Epub 2012/02/18. eng.
4. Nishioka K, Doki Y, Shiozaki H, Yamamoto H, Tamura S, Yasuda T, et al. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. *Br J Cancer.* 2001 Aug 3;85(3):412-21. PubMed PMID: 11487274. Pubmed Central PMCID: 2364065. Epub 2001/08/07. eng.
5. Dong J, Zeng BH, Xu LH, Wang JY, Li MZ, Zeng MS, et al. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. *J Transl Med.* 2010;8:81. PubMed PMID: 20813067. Pubmed Central PMCID: 2941748. Epub 2010/09/04. eng.
6. Cao X, Li Y, Luo RZ, He LR, Yang J, Zeng MS, et al. Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma. *Ann Thorac Surg.* 2012 May;93(5):1674-80. PubMed PMID: 22429674. Epub 2012/03/21. eng.
7. You YJ, Chen YP, Zheng XX, Meltzer SJ, Zhang H. Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. *Cancer Lett.* 2012 Feb 28;315(2):138-44. PubMed PMID: 22099875. Pubmed Central PMCID: 3248961. Epub 2011/11/22. eng.
8. Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM, et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. *Clin Cancer Res.* 2007 Jun 1;13(11):3174-81. PubMed PMID: 17545520. Pubmed Central PMCID: 3074612. Epub 2007/06/05. eng.
9. Hatakeyama M. Helicobacter pylori and gastric carcinogenesis. *J Gastroenterol.* 2009;44(4):239-48. PubMed PMID: 19271114. Epub 2009/03/10. eng.
10. Yamazaki S, Yamakawa A, Ito Y, Ohtani M, Higashi H, Hatakeyama M, et al. The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa. *J Infect Dis.* 2003 Jan 15;187(2):334-7. PubMed PMID: 12552462. Epub 2003/01/29. eng.
11. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. *Cancer Metastasis Rev.* 2008 Jun;27(2):179-92. PubMed PMID: 18286234. Epub 2008/02/21. eng.
12. Kim JS, Shin OR, Kim HK, Cho YS, An CH, Lim KW, et al. Overexpression of protein phosphatase non-receptor type 11 (PTPN11) in gastric carcinomas. *Dig Dis Sci.* 2010 Jun;55(6):1565-9. PubMed PMID: 19690960. Epub 2009/08/20. eng.
13. Shin CM, Kim N, Park JH, Kang GH, Kim JS, Jung HC, et al. Prediction of the risk for gastric cancer using candidate methylation markers in the non-neoplastic gastric mucosae. *J Pathol.* 2012 Mar;226(4):654-65. PubMed PMID: 22252584. Epub 2012/01/19. eng.
14. Ksiao F, Ziadi S, Amara K, Korbi S, Trimeche M. Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma. *Clin Chim Acta.* 2009 Jun 27;404(2):128-33. PubMed PMID: 19336228. Epub 2009/04/02. eng.
15. Yang SH, Seo MY, Jeong HJ, Jeung HC, Shin J, Kim SC, et al. Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients. *Clin Cancer Res.* 2005 Jan 15;11(2 Pt 1):612-20. PubMed PMID: 15701848. Epub 2005/02/11. eng.

16. Wang J, Liu B, Chen X, Su L, Wu P, Wu J, et al. PTP1B expression contributes to gastric cancer progression. *Med Oncol*. 2012 Jun;29(2):948-56. PubMed PMID: 21442314. Epub 2011/03/29. eng.
17. Lessard L, Stuiblé M, Tremblay ML. The two faces of PTP1B in cancer. *Biochim Biophys Acta*. 2010 Mar;1804(3):613-9. PubMed PMID: 19782770. Epub 2009/09/29. eng.
18. Wu CW, Chen JH, Kao HL, Li AF, Lai CH, Chi CW, et al. PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma. *Anticancer Res*. 2006 Mar-Apr;26(2B):1643-9. PubMed PMID: 16619586. Epub 2006/04/20. eng.
19. Hou SW, Zhi HY, Pohl N, Loesch M, Qi XM, Li RS, et al. PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction. *Cancer Res*. 2010 Apr 1;70(7):2901-10. PubMed PMID: 20332238. Epub 2010/03/25. eng.
20. Gu MX, York JD, Warshawsky I, Majerus PW. Identification, cloning, and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1. *Proc Natl Acad Sci U S A*. 1991 Jul 1;88(13):5867-71. PubMed PMID: 1648233. Epub 1991/07/01. eng.
21. Gu M, Meng K, Majerus PW. The effect of overexpression of the protein tyrosine phosphatase PTPMEG on cell growth and on colony formation in soft agar in COS-7 cells. *Proc Natl Acad Sci U S A*. 1996 Nov 12;93(23):12980-5. PubMed PMID: 8917530. Epub 1996/11/12. eng.
22. Wu CW, Kao HL, Li AF, Chi CW, Lin WC. Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. *Cancer Lett*. 2006 Oct 8;242(1):95-103. PubMed PMID: 16338072. Epub 2005/12/13. eng.
23. Zeng L, Si X, Yu WP, Le HT, Ng KP, Teng RM, et al. PTP alpha regulates integrin-stimulated FAK autophosphorylation and cytoskeletal rearrangement in cell spreading and migration. *J Cell Biol*. 2003 Jan 6;160(1):137-46. PubMed PMID: 12515828. Epub 2003/01/08. eng.
24. Pallen CJ. Protein tyrosine phosphatase alpha (PTPalph): a Src family kinase activator and mediator of multiple biological effects. *Curr Top Med Chem*. 2003;3(7):821-35. PubMed PMID: 12678847. Epub 2003/04/08. eng.
25. Harder KW, Moller NP, Peacock JW, Jirik FR. Protein-tyrosine phosphatase alpha regulates Src family kinases and alters cell-substratum adhesion. *J Biol Chem*. 1998 Nov 27;273(48):31890-900. PubMed PMID: 9822658. Epub 1998/11/21. eng.
26. Wang JF, Dai DQ. Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer. *World J Gastroenterol*. 2007 Nov 21;13(43):5692-8. PubMed PMID: 17963294. Epub 2007/10/30. eng.
27. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. *Science*. 2004 May 21;304(5674):1164-6. PubMed PMID: 15155950. Epub 2004/05/25. eng.
28. Lee JW, Jeong EG, Lee SH, Nam SW, Kim SH, Lee JY, et al. Mutational analysis of PTPRT phosphatase domains in common human cancers. *APMIS*. 2007 Jan;115(1):47-51. PubMed PMID: 17223850. Epub 2007/01/17. eng.
29. Matozaki T, Suzuki T, Uchida T, Inazawa J, Ariyama T, Matsuda K, et al. Molecular cloning of a human transmembrane-type protein tyrosine phosphatase and its expression in gastrointestinal cancers. *J Biol Chem*. 1994 Jan 21;269(3):2075-81. PubMed PMID: 8294459. Epub 1994/01/21. eng.
30. Bang YJ, Kwon JH, Kang SH, Kim JW, Yang YC. Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. *Biochem Biophys Res Commun*. 1998 Sep 8;250(1):43-7. PubMed PMID: 9735328. Epub 1998/09/15. eng.

31. Miskad UA, Semba S, Kato H, Yokozaki H. Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. *Pathobiology*. 2004;71(4):176-84. PubMed PMID: 15263806. Epub 2004/07/21. eng.
32. Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, et al. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. *Virchows Arch*. 2007 Mar;450(3):303-10. PubMed PMID: 17235563. Epub 2007/01/20. eng.
33. Wang Z, Cai SR, He YL, Zhan WH, Chen CQ, Cui J, et al. High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients. *Ann Surg Oncol*. 2009 Jan;16(1):208-19. PubMed PMID: 19009246. Epub 2008/11/15. eng.
34. Li ZR, Wang Z, Zhu BH, He YL, Peng JS, Cai SR, et al. Association of tyrosine PRL-3 phosphatase protein expression with peritoneal metastasis of gastric carcinoma and prognosis. *Surg Today*. 2007;37(8):646-51. PubMed PMID: 17643206. Epub 2007/07/24. eng.
35. Dai N, Lu AP, Shou CC, Li JY. Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer. *World J Gastroenterol*. 2009 Mar 28;15(12):1499-505. PubMed PMID: 19322925. Epub 2009/03/27. eng.
36. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Waraya M, et al. Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer. *BMC Cancer*. 2011;11:122. PubMed PMID: 21466710. Epub 2011/04/07. eng.
37. Korff S, Woerner SM, Yuan YP, Bork P, von Knebel Doeberitz M, Gebert J. Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability. *BMC Cancer*. 2008;8:329. PubMed PMID: 19000305. Pubmed Central PMCID: 2586028. Epub 2008/11/13. eng.
38. Mori Y, Yin J, Sato F, Sterian A, Simms LA, Selaru FM, et al. Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. *Cancer Res*. 2004 Apr 1;64(7):2434-8. PubMed PMID: 15059896. Epub 2004/04/03. eng.
39. Sato T, Irie S, Kitada S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. *Science*. 1995 Apr 21;268(5209):411-5. PubMed PMID: 7536343. Epub 1995/04/21. eng.
40. Miyazaki T, Atarashi Y, Yasumura S, Minatoya I, Ogawa K, Iwamoto M, et al. Fas-associated phosphatase-1 promotes Fas-mediated apoptosis in human colon cancer cells: novel function of FAP-1. *J Gastroenterol Hepatol*. 2006 Jan;21(1 Pt 1):84-91. PubMed PMID: 16706817. Epub 2006/05/19. eng.
41. Yao H, Song E, Chen J, Hamar P. Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer. *Br J Cancer*. 2004 Nov 1;91(9):1718-25. PubMed PMID: 15494722. Pubmed Central PMCID: 2409949. Epub 2004/10/21. eng.
42. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U, et al. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. *J Mol Med (Berl)*. 2007 Mar;85(3):293-304. PubMed PMID: 17143621. Epub 2006/12/05. eng.
43. Zhu S, Bjorge JD, Fujita DJ. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. *Cancer Res*. 2007 Nov 1;67(21):10129-37. PubMed PMID: 17974954. Epub 2007/11/03. eng.
44. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. *Neoplasia*. 2005 Jun;7(6):545-55. PubMed PMID: 16036105. Pubmed Central PMCID: 1501283. Epub 2005/07/23. eng.

45. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. *Am J Pathol.* 2005 Oct;167(4):969-80. PubMed PMID: 16192633. Pubmed Central PMCID: 1603671. Epub 2005/09/30. eng.
46. Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. *Proc Natl Acad Sci U S A.* 2007 Mar 6;104(10):4060-4. PubMed PMID: 17360477. Pubmed Central PMCID: 1802729. Epub 2007/03/16. eng.
47. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. *Proc Natl Acad Sci U S A.* 2009 Jun 9;106(23):9435-40. PubMed PMID: 19478061. Pubmed Central PMCID: 2687998. Epub 2009/05/30. eng.
48. Zhao Y, Zhang X, Guda K, Lawrence E, Sun Q, Watanabe T, et al. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. *Proc Natl Acad Sci U S A.* 2010 Feb 9;107(6):2592-7. PubMed PMID: 20133777. Pubmed Central PMCID: 2823898. Epub 2010/02/06. eng.
49. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. *Science.* 2006;314(268):268-74.
50. Funato K, Yamazumi Y, Oda T, Akiyama T. Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. *Experimental and Therapeutic Medicine.* 2011;2:457-63.
51. Tabiti K, Smith DR, Goh HS, Pallen CJ. Increased mRNA expression of the receptor-like protein tyrosine phosphatase alpha in late stage colon carcinomas. *Cancer Lett.* 1995 Jul 13;93(2):239-48. PubMed PMID: 7621435. Epub 1995/07/13. eng.
52. Krndija D, Schmid H, Eismann JL, Lothar U, Adler G, Oswald F, et al. Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility. *Oncogene.* 2010 May 6;29(18):2724-38. PubMed PMID: 20208566. Epub 2010/03/09. eng.
53. Zheng X, Resnick RJ, Shalloway D. Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi. *Int J Cancer.* 2008 May 1;122(9):1999-2007. PubMed PMID: 18183590. Epub 2008/01/10. eng.
54. Seo Y, Matozaki T, Tsuda M, Hayashi Y, Itoh H, Kasuga M. Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers. *Biochem Biophys Res Commun.* 1997 Feb 24;231(3):705-11. PubMed PMID: 9070877. Epub 1997/02/24. eng.
55. Sadakata H, Okazawa H, Sato T, Supriatna Y, Ohnishi H, Kusakari S, et al. SAP-1 is a microvillus-specific protein tyrosine phosphatase that modulates intestinal tumorigenesis. *Genes Cells.* 2009 Mar;14(3):295-308. PubMed PMID: 19170756. Epub 2009/01/28. eng.
56. Malentacchi F, Marzocchini R, Gelmini S, Orlando C, Serio M, Ramponi G, et al. Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers. *Biochem Biophys Res Commun.* 2005 Sep 2;334(3):875-83. PubMed PMID: 16036221. Epub 2005/07/23. eng.
57. Chiarugi P, Taddei ML, Schiavone N, Papucci L, Giannoni E, Fiaschi T, et al. LMW-PTP is a positive regulator of tumor onset and growth. *Oncogene.* 2004;23:3905-14.
58. Mollevi DG, Aytes A, Padulles L, Martinez-Iniesta M, Baixeras N, Salazar R, et al. PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. *Br J Cancer.* 2008 Nov 18;99(10):1718-25. PubMed PMID: 19002188. Epub 2008/11/13. eng.
59. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, et al. A phosphatase associated with metastasis of colorectal cancer. *Science.* 2001;294(5545):1343-6.

60. Jiang Y, Liu XQ, Rajput A, Geng L, Ongchin M, Zeng Q, et al. Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis. *Cancer Res.* Jan 1;71(1):234-44. PubMed PMID: 21084277. Epub 2010/11/19. eng.
61. Wang H, Quah SY, Dong JM, Manser E, Tang JP, Zeng Q. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. *Cancer Res.* 2007 Apr 1;67(7):2922-6. PubMed PMID: 17409395. Epub 2007/04/06. eng.
62. Ruivenkamp C, Hermsen M, Postma C, Klous A, Baak J, Meijer G, et al. LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21. *Oncogene.* 2003 May 29;22(22):3472-4. PubMed PMID: 12776199. Epub 2003/05/31. eng.
63. Balavenkatraman KK, Jandt E, Friedrich K, Kautenburger T, Pool-Zobel BL, Ostman A, et al. DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients. *Oncogene.* 2006 Oct 12;25(47):6319-24. PubMed PMID: 16682945. Epub 2006/05/10. eng.
64. Lin MS, Huang JX, Chen WC, Zhang BF, Fang J, Zhou Q, et al. Expression of PPARgamma and PTEN in human colorectal cancer: An immunohistochemical study using tissue microarray methodology. *Oncol Lett.* 2011 Nov;2(6):1219-24. PubMed PMID: 22848291. Epub 2012/08/01. Eng.
65. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, et al. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. *Am J Pathol.* 1996 Nov;149(5):1553-64. PubMed PMID: 8909245. Pubmed Central PMCID: 1865259. Epub 1996/11/01. eng.
66. Montagut C, Arumi MIM, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, et al. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. *British Journal of Cancer.* 2010;102:1137-44.
67. Ruivenkamp CA, van Wezel T, Zanon C, Stassen AP, Vlcek C, Csikos T, et al. Ptprij is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. *Nat Genet.* 2002 Jul;31(3):295-300. PubMed PMID: 12089527. Epub 2002/06/29. eng.
68. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. *Proc Natl Acad Sci U S A.* 1996 Apr 16;93(8):3636-41. PubMed PMID: 8622988. Epub 1996/04/16. eng.
69. Schild C, Wirth M, Reichert M, Schmid RM, Saur D, Schneider G. PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells. *Mol Carcinog.* 2009 Dec;48(12):1149-58. PubMed PMID: 19603422. Epub 2009/07/16. eng.
70. Pham NA, Schwock J, Iakovlev V, Pond G, Hedley DW, Tsao MS. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. *BMC Cancer.* 2008;8:43. PubMed PMID: 18254976. Epub 2008/02/08. eng.
71. Nitsche C, Edderkaoui M, Moore RM, Eibl G, Kasahara N, Treger J, et al. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. *Gastroenterology.* 2012 Feb;142(2):377-87 e1-5. PubMed PMID: 22044669. Epub 2011/11/03. eng.
72. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. *Mol Cell.* 2005 Apr 1;18(1):13-24. PubMed PMID: 15808505. Epub 2005/04/06. eng.
73. Brognard J, Sierrecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. *Mol Cell.* 2007 Mar 23;25(6):917-31. PubMed PMID: 17386267. Epub 2007/03/28. eng.

74. Okami K, Wu L, Riggins G, Cairns P, Goggins M, Evron E, et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. *Cancer Res.* 1998 Feb 1;58(3):509-11. PubMed PMID: 9458098. Epub 1998/02/11. eng.
75. Farrow B, Evers BM. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. *Biochem Biophys Res Commun.* 2003 Jan 31;301(1):50-3. PubMed PMID: 12535639. Epub 2003/01/22. eng.
76. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. *Cancer Res.* 2000 Mar 15;60(6):1541-5. PubMed PMID: 10749120. Epub 2000/04/05. eng.
77. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. *Cell.* 1998 Oct 2;95(1):29-39. PubMed PMID: 9778245. Epub 1998/10/20. eng.
78. Chow JY, Dong H, Quach KT, Van Nguyen PN, Chen K, Carethers JM. TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells. *Am J Physiol Gastrointest Liver Physiol.* 2008 Apr;294(4):G899-905. PubMed PMID: 18239055. Epub 2008/02/02. eng.
79. Chow JY, Ban M, Wu HL, Nguyen F, Huang M, Chung H, et al. TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. *Am J Physiol Gastrointest Liver Physiol.* 2010 Feb;298(2):G275-82. PubMed PMID: 19940030. Epub 2009/11/27. eng.
80. Maurice D, Pierreux CE, Howell M, Wilentz RE, Owen MJ, Hill CS. Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability. *J Biol Chem.* 2001 Nov 16;276(46):43175-81. PubMed PMID: 11553622. Epub 2001/09/13. eng.
81. Antonello D, Moore PS, Zamboni G, Falconi M, Scarpa A. Absence of mutations in the transforming growth factor-beta inducible early gene 1, TIEG1, in pancreatic cancer. *Cancer Lett.* 2002 Sep 26;183(2):179-83. PubMed PMID: 12065093. Epub 2002/06/18. eng.
82. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. *Clin Cancer Res.* 2001 Dec;7(12):4115-21. PubMed PMID: 11751510. Epub 2001/12/26. eng.
83. Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. *Annu Rev Cell Dev Biol.* 2005;21:659-93. PubMed PMID: 16212511. Epub 2005/10/11. eng.
84. Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. *Cell.* 2006 Jun 2;125(5):915-28. PubMed PMID: 16751101. Epub 2006/06/06. eng.
85. Cejudo-Marin R, Tarrega C, Nunes-Xavier CE, Pulido R. Caspase-3 cleavage of DUSP6/MKP3 at the interdomain region generates active MKP3 fragments that regulate ERK1/2 subcellular localization and function. *J Mol Biol.* 2012 Jun 29;420(1-2):128-38. PubMed PMID: 22504224. Epub 2012/04/17. eng.
86. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. *Am J Pathol.* 2003 Jun;162(6):1807-15. PubMed PMID: 12759238. Epub 2003/05/22. eng.
87. Furukawa T, Yatsuoka T, Youssef EM, Abe T, Yokoyama T, Fukushige S, et al. Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. *Cytogenet Cell Genet.* 1998;82(3-4):156-9. PubMed PMID: 9858808. Epub 1998/12/22. eng.
88. Furukawa T, Fujisaki R, Yoshida Y, Kanai N, Sunamura M, Abe T, et al. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. *Mod Pathol.* 2005 Aug;18(8):1034-42. PubMed PMID: 15832194. Epub 2005/04/16. eng.

89. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. *Clin Cancer Res.* 1999 Jan;5(1):119-27. PubMed PMID: 9918209. Epub 1999/01/26. eng.
90. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. *Nature.* 1997 Aug 7;388(6642):548-54. PubMed PMID: 9252186. Epub 1997/08/07. eng.
91. Kray AE, Carter RS, Pennington KN, Gomez RJ, Sanders LE, Llanes JM, et al. Positive regulation of IkappaB kinase signaling by protein serine/threonine phosphatase 2A. *J Biol Chem.* 2005 Oct 28;280(43):35974-82. PubMed PMID: 16126728. Epub 2005/08/30. eng.
92. Li W, Chen Z, Zong Y, Gong F, Zhu Y, Lv J, et al. PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKalpha and sustained activation of the NF-kappaB pathway. *Cancer Lett.* 2011 May 28;304(2):117-27. PubMed PMID: 21376459. Epub 2011/03/08. eng.
93. Li W, Chen Z, Gong FR, Zong Y, Chen K, Li DM, et al. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway. *Eur J Cancer.* 2011 Nov;47(17):2654-64. PubMed PMID: 21958460. Epub 2011/10/01. eng.
94. Muller P, Henn W, Niedermayer I, Ketter R, Feiden W, Steudel WI, et al. Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. *Clin Cancer Res.* 1999 Nov;5(11):3569-77. PubMed PMID: 10589773. Epub 1999/12/10. eng.
95. Kobayashi I, Shidara K, Okuno S, Yamada S, Imanishi Y, Mori K, et al. Higher serum bone alkaline phosphatase as a predictor of mortality in male hemodialysis patients. *Life Sci.* 2012 Jan 30;90(5-6):212-8. PubMed PMID: 22154904. Epub 2011/12/14. eng.
96. Chuang YC, Lin AT, Chen KK, Chang YH, Chen MT, Chang LS. Paraneoplastic elevation of serum alkaline phosphatase in renal cell carcinoma: incidence and implication on prognosis. *J Urol.* 1997 Nov;158(5):1684-7. PubMed PMID: 9334578. Epub 1997/10/23. eng.
97. Rajarubendra N, Bolton D, Lawrentschuk N. Diagnosis of bone metastases in urological malignancies--an update. *Urology.* 2010 Oct;76(4):782-90. PubMed PMID: 20346492. Epub 2010/03/30. eng.
98. Lavecchia A, Di Giovanni C, Novellino E. Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review. *Expert Opin Ther Pat.* Mar;20(3):405-25. PubMed PMID: 20166845. Epub 2010/02/20. eng.
99. Yu XY, Zhang Z, Zhang GJ, Guo KF, Kong CZ. Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features. *Asian Pac J Cancer Prev.*13(3):931-5. PubMed PMID: 22631674. Epub 2012/05/29. eng.
100. Mizuno R, Oya M, Hara S, Matsumoto M, Horiguchi A, Ohigashi T, et al. Modulation of bcl-2 family proteins in MAPK independent apoptosis induced by a cdc25 phosphatase inhibitor Cpd 5 in renal cancer cells. *Oncol Rep.* 2005 Sep;14(3):639-44. PubMed PMID: 16077967. Epub 2005/08/04. eng.
101. Castro ME, Ferrer I, Cascon A, Guijarro MV, Leonart M, Ramon y Cajal S, et al. PPP1CA contributes to the senescence program induced by oncogenic Ras. *Carcinogenesis.* 2008 Mar;29(3):491-9. PubMed PMID: 18204081. Epub 2008/01/22. eng.
102. Brems-Eskildsen AS, Zieger K, Toldbod H, Holcomb C, Higuchi R, Mansilla F, et al. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. *BMC Cancer.*10:646. PubMed PMID: 21106093. Pubmed Central PMCID: 3001447. Epub 2010/11/26. eng.

103. Carlucci A, Porpora M, Garbi C, Galgani M, Santoriello M, Mascolo M, et al. PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells. *J Biol Chem*. Dec 10;285(50):39260-70. PubMed PMID: 20923765. Pubmed Central PMCID: 2998146. Epub 2010/10/07. eng.
104. Li X, Tan X, Yu Y, Chen H, Chang W, Hou J, et al. D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta. *Cancer*. 2011 Sep 15;117(18):4201-11. PubMed PMID: 21387281. Epub 2011/03/10. eng.
105. Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo Park C. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. *J Surg Oncol*. 2003 Nov;84(3):166-72. PubMed PMID: 14598361. Epub 2003/11/05. eng.
106. Hager M, Haufe H, Kemmerling R, Mikuz G, Kolbitsch C, Moser PL. PTEN expression in renal cell carcinoma and oncocytoma and prognosis. *Pathology*. 2007 Oct;39(5):482-5. PubMed PMID: 17886097. Epub 2007/09/22. eng.
107. Hager M, Haufe H, Lusuardi L, Schmeller N, Kolbitsch C. PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases. *Cancer Invest*. Aug;29(7):427-38. PubMed PMID: 21696297. Epub 2011/06/24. eng.
108. Mundhenk J, Hennenlotter J, Zug L, Alloussi SH, Todenhoefer T, Gakis G, et al. Evidence for PTEN-independent Akt activation and Akt-independent p27(Kip1) expression in advanced bladder cancer. *Oncol Lett*. 2011 Nov;2(6):1089-93. PubMed PMID: 22848272. Pubmed Central PMCID: 3406569. Epub 2012/08/01. Eng.
109. Schneider E, Keppler R, Prawitt D, Steinwender C, Roos FC, Thuroff JW, et al. Migration of renal tumor cells depends on dephosphorylation of Shc by PTEN. *Int J Oncol*. Mar;38(3):823-31. PubMed PMID: 21206972. Epub 2011/01/06. eng.
110. Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modiano JF, et al. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. *Mol Cancer*. 2007;6:16. PubMed PMID: 17300726. Pubmed Central PMCID: 1803787. Epub 2007/02/16. eng.
111. Liu J, Babaian DC, Liebert M, Steck PA, Kagan J. Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. *Mol Carcinog*. 2000 Nov;29(3):143-50. PubMed PMID: 11108659. Epub 2000/12/07. eng.
112. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. *Genes Dev*. 2009 Mar 15;23(6):675-80. PubMed PMID: 19261747. Pubmed Central PMCID: 2661614. Epub 2009/03/06. eng.
113. Shorning BY, Griffiths D, Clarke AR. Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. *PLoS One*. 2011;6(1):e16209. PubMed PMID: 21283818. Pubmed Central PMCID: 3023771. Epub 2011/02/02. eng.
114. Lai MW, Chen TC, Pang ST, Yeh CT. Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells. *Urol Oncol*. Mar 9. PubMed PMID: 21396835. Epub 2011/03/15. Eng.
115. Mizuno R, Oya M, Shiomi T, Marumo K, Okada Y, Murai M. Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells. *J Urol*. 2004 Aug;172(2):723-7. PubMed PMID: 15247770. Epub 2004/07/13. eng.
116. Wu S, Wang Y, Sun L, Zhang Z, Jiang Z, Qin Z, et al. Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma. *BMC Cancer*. 2011;11:413. PubMed PMID: 21943117. Pubmed Central PMCID: 3198720. Epub 2011/09/29. eng.

117. Su WP, Tu IH, Hu SW, Yeh HH, Shieh DB, Chen TY, et al. HER-2/neu raises SHP-2, stops IFN-gamma anti-proliferation in bladder cancer. *Biochem Biophys Res Commun.* 2007 Apr 27;356(1):181-6. PubMed PMID: 17346677. Epub 2007/03/10. eng.
118. Kuroda N, Hayashi Y, Matozaki T, Hanioka K, Gotoh A, Wang W, et al. Differential expression of SHP2, a protein-tyrosine phosphatase with SRC homology-2 domains, in various types of renal tumour. *Virchows Arch.* 1998 Oct;433(4):331-9. PubMed PMID: 9808435. Epub 1998/11/10. eng.
119. Liu T, Li L, Yang W, Jia H, Xu M, Bi J, et al. iASPP is important for bladder cancer cell proliferation. *Oncol Res.* 19(3-4):125-30. PubMed PMID: 21473288. Epub 2011/04/09. eng.
120. Bell HS, Ryan KM. iASPP inhibition: increased options in targeting the p53 family for cancer therapy. *Cancer Res.* 2008 Jul 1;68(13):4959-62. PubMed PMID: 18593889. Epub 2008/07/03. eng.
121. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science.* 1997 Mar 28;275(5308):1943-7. PubMed PMID: 9072974. Epub 1997/03/28. eng.
122. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nat Genet.* 1997 Apr;15(4):356-62. PubMed PMID: 9090379. Epub 1997/04/01. eng.
123. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. *Cancer Res.* 1997 Nov 15;57(22):4997-5000. PubMed PMID: 9371490. Epub 1997/11/26. eng.
124. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. *Cancer Res.* 1997 Dec 1;57(23):5221-5. PubMed PMID: 9393738. Epub 1997/12/11. eng.
125. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. *Proc Natl Acad Sci U S A.* 1998 Apr 28;95(9):5246-50. PubMed PMID: 9560261. Pubmed Central PMCID: 20246. Epub 1998/06/06. eng.
126. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. *Cancer Res.* 1998 Jul 1;58(13):2720-3. PubMed PMID: 9661880. Epub 1998/07/14. eng.
127. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. *PLoS Biol.* 2003 Dec;1(3):E59. PubMed PMID: 14691534. Pubmed Central PMCID: 270016. Epub 2003/12/24. eng.
128. Chow LM, Baker SJ. PTEN function in normal and neoplastic growth. *Cancer Lett.* 2006 Sep 28;241(2):184-96. PubMed PMID: 16412571. Epub 2006/01/18. eng.
129. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. *Nat Med.* 2004 Jun;10(6):594-601. PubMed PMID: 15156201. Epub 2004/05/25. eng.
130. Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. *Curr Biol.* 2005 Oct 25;15(20):1839-46. PubMed PMID: 16243031. Epub 2005/10/26. eng.
131. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. *J Clin Oncol.* 2004 Jul 15;22(14):2954-63. PubMed PMID: 15254063. Epub 2004/07/16. eng.
132. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer.* 2009 Aug;9(8):550-62. PubMed PMID: 19629070. Epub 2009/07/25. eng.

133. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. *Endocrinology*. 2001 Nov;142(11):4795-805. PubMed PMID: 11606446. Epub 2001/10/19. eng.
134. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. *Oncogene*. 2006 Jan 19;25(3):329-37. PubMed PMID: 16421604. Epub 2006/01/20. eng.
135. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell*. 2003 Sep;4(3):209-21. PubMed PMID: 14522255. Epub 2003/10/03. eng.
136. Li P, Nicosia SV, Bai W. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. *J Biol Chem*. 2001 Jun 8;276(23):20444-50. PubMed PMID: 11278645. Epub 2001/03/30. eng.
137. Lin HK, Hu YC, Lee DK, Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. *Mol Endocrinol*. 2004 Oct;18(10):2409-23. PubMed PMID: 15205473. Epub 2004/06/19. eng.
138. Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y, et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. *Mol Cell*. 2005 Oct 7;20(1):33-44. PubMed PMID: 16209943. Epub 2005/10/08. eng.
139. Fernandez-Marcos PJ, Abu-Baker S, Joshi J, Galvez A, Castilla EA, Canamero M, et al. Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma. *Proc Natl Acad Sci U S A*. 2009 Aug 4;106(31):12962-7. PubMed PMID: 19470463. Pubmed Central PMCID: 2722271. Epub 2009/05/28. eng.
140. Cohen PT. Protein phosphatase 1--targeted in many directions. *J Cell Sci*. 2002 Jan 15;115(Pt 2):241-56. PubMed PMID: 11839776. Epub 2002/02/13. eng.
141. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. *Biochem J*. 2001 Feb 1;353(Pt 3):417-39. PubMed PMID: 11171037. Pubmed Central PMCID: 1221586. Epub 2001/02/15. eng.
142. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. *Curr Opin Genet Dev*. 2005 Feb;15(1):34-41. PubMed PMID: 15661531. Epub 2005/01/22. eng.
143. Xu Y, Xing Y, Chen Y, Chao Y, Lin Z, Fan E, et al. Structure of the protein phosphatase 2A holoenzyme. *Cell*. 2006 Dec 15;127(6):1239-51. PubMed PMID: 17174897. Epub 2006/12/19. eng.
144. Singh AP, Bafna S, Chaudhary K, Venkatraman G, Smith L, Eudy JD, et al. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. *Cancer Lett*. 2008 Jan 18;259(1):28-38. PubMed PMID: 17977648. Pubmed Central PMCID: 2784916. Epub 2007/11/06. eng.
145. Cheng Y, Liu W, Kim ST, Sun J, Lu L, Zheng SL, et al. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. *Cancer Genet*. 2011 Jul;204(7):375-81. PubMed PMID: 21872824. Epub 2011/08/30. eng.
146. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. *Mol Cell Biol*. 2003 Dec;23(24):9389-404. PubMed PMID: 14645548. Pubmed Central PMCID: 309640. Epub 2003/12/04. eng.
147. Chen S, Kesler CT, Paschal BM, Balk SP. Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. *J Biol Chem*. 2009 Sep 18;284(38):25576-84. PubMed PMID: 19622840. Pubmed Central PMCID: 2757959. Epub 2009/07/23. eng.

148. Kim SW, Jung HK, Kim MY. Induction of p27(kip1) by 2,4,3',5'- tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. *Arch Pharm Res.* 2008 Sep;31(9):1187-94. PubMed PMID: 18816901. Epub 2008/09/27. eng.
149. Yu N, Kozlowski JM, Park, II, Chen L, Zhang Q, Xu D, et al. Overexpression of transforming growth factor beta1 in malignant prostate cells is partly caused by a runaway of TGF-beta1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-beta type I receptor. *Urology.* 2010 Dec;76(6):1519 e8-13. PubMed PMID: 21030067. Pubmed Central PMCID: 2997920. Epub 2010/10/30. eng.
150. Bhardwaj A, Singh S, Srivastava SK, Honkanen RE, Reed E, Singh AP. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. *Mol Cancer Ther.* 2011 May;10(5):720-31. PubMed PMID: 21393425. Epub 2011/03/12. eng.
151. Corcoran NM, Najdovska M, Costello AJ. Inorganic selenium retards progression of experimental hormone refractory prostate cancer. *J Urol.* 2004 Feb;171(2 Pt 1):907-10. PubMed PMID: 14713851. Epub 2004/01/10. eng.
152. Corcoran NM, Hovens CM, Michael M, Rosenthal MA, Costello AJ. Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. *Br J Cancer.* 2010 Aug 10;103(4):462-8. PubMed PMID: 20648008. Pubmed Central PMCID: 2939789. Epub 2010/07/22. eng.
153. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? *Nat Rev Cancer.* 2007 Jul;7(7):495-507. PubMed PMID: 17568790. Epub 2007/06/15. eng.
154. Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. *Oncogene.* 2003 Feb 6;22(5):734-9. PubMed PMID: 12569365. Epub 2003/02/06. eng.
155. Chiu YT, Han HY, Leung SC, Yuen HF, Chau CW, Guo Z, et al. CDC25A functions as a novel Ar corepressor in prostate cancer cells. *J Mol Biol.* 2009 Jan 16;385(2):446-56. PubMed PMID: 19013180. Epub 2008/11/18. eng.
156. Ozen M, Ittmann M. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. *Clin Cancer Res.* 2005 Jul 1;11(13):4701-6. PubMed PMID: 16000564. Epub 2005/07/08. eng.
157. Prasad S, Kaur J, Roy P, Kalra N, Shukla Y. Theaflavins induce G2/M arrest by modulating expression of p21waf1/cip1, cdc25C and cyclin B in human prostate carcinoma PC-3 cells. *Life Sci.* 2007 Oct 13;81(17-18):1323-31. PubMed PMID: 17936851. Epub 2007/10/16. eng.
158. Valencia AM, Oliva JL, Bodega G, Chiloeches A, Lopez-Ruiz P, Prieto JC, et al. Identification of a protein-tyrosine phosphatase (SHP1) different from that associated with acid phosphatase in rat prostate. *FEBS Lett.* 1997 Apr 7;406(1-2):42-8. PubMed PMID: 9109383. Epub 1997/04/07. eng.
159. Zapata PD, Ropero RM, Valencia AM, Buscail L, Lopez JI, Martin-Orozco RM, et al. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. *J Clin Endocrinol Metab.* 2002 Feb;87(2):915-26. PubMed PMID: 11836342. Epub 2002/02/12. eng.
160. Cariaga-Martinez AE, Lorenzati MA, Riera MA, Cubilla MA, De La Rossa A, Giorgio EM, et al. Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression. *Adv Urol.* 2009:723831. PubMed PMID: 19365586. Pubmed Central PMCID: 2667939. Epub 2009/04/15. eng.

161. Tassidis H, Brokken LJ, Jirstrom K, Ehrnstrom R, Ponten F, Ulmert D, et al. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer. *Int J Cancer*. 2010 May 15;126(10):2296-307. PubMed PMID: 19795453. Epub 2009/10/02. eng.
162. Rodriguez-Ubreva FJ, Cariaga-Martinez AE, Cortes MA, Romero-De Pablos M, Ropero S, Lopez-Ruiz P, et al. Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery. *Oncogene*. 2010 Jan 21;29(3):345-55. PubMed PMID: 19838216. Epub 2009/10/20. eng.
163. Tassidis H, Brokken LJ, Jirstrom K, Bjartell A, Ulmert D, Harkonen P, et al. Low expression of SHP-2 is associated with less favorable prostate cancer outcomes. *Tumour Biol*. 2012 Nov 29. PubMed PMID: 23192641. Epub 2012/11/30. Eng.
164. Matozaki T, Murata Y, Saito Y, Okazawa H, Ohnishi H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. *Cancer Sci*. 2009 Oct;100(10):1786-93. PubMed PMID: 19622105. Epub 2009/07/23. eng.
165. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin*. 2010 Sep-Oct;60(5):277-300. PubMed PMID: 20610543. Epub 2010/07/09. eng.
166. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. *Hum Pathol*. 1998 Sep;29(9):924-31. PubMed PMID: 9744308. Epub 1998/09/23. eng.
167. Fujimoto T, Nanjyo H, Fukuda J, Nakamura A, Mizunuma H, Yaegashi N, et al. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. *Gynecol Oncol*. 2009 Feb;112(2):342-7. PubMed PMID: 19062082. Epub 2008/12/09. eng.
168. Dellinger TH, Monk BJ. Systemic therapy for recurrent endometrial cancer: a review of North American trials. *Expert Rev Anticancer Ther*. 2009 Jul;9(7):905-16. PubMed PMID: 19589030. Epub 2009/07/11. eng.
169. Zhang Q, Claret FX. Phosphatases: the new brakes for cancer development? *Enzyme Res*. 2012;2012:659649. PubMed PMID: 22121480. Pubmed Central PMCID: 3206369. Epub 2011/11/29. eng.
170. McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. *J Pathol*. 2011 Apr;223(5):567-73. PubMed PMID: 21381030. Epub 2011/03/08. eng.
171. Chiappinelli KB, Rimel BJ, Massad LS, Goodfellow PJ. Infrequent methylation of the DUSP6 phosphatase in endometrial cancer. *Gynecol Oncol*. 2010 Oct;119(1):146-50. PubMed PMID: 20638106. Pubmed Central PMCID: 2939303. Epub 2010/07/20. eng.
172. Gloria-Bottini F, Spina C, Nicotra M, Saccucci P, Ambrosi S, Bottini E. Acid phosphatase locus 1 genetic polymorphism and cancer grading. *Am J Med Sci*. 2012 Jul;344(1):32-4. PubMed PMID: 22692348. Epub 2012/06/14. eng.
173. Allard JE, Chandramouli GV, Stagliano K, Hood BL, Litzi T, Shoji Y, et al. Analysis of PSPHL as a Candidate Gene Influencing the Racial Disparity in Endometrial Cancer. *Front Oncol*. 2012;2:65. PubMed PMID: 22783543. Pubmed Central PMCID: 3389395. Epub 2012/07/12. eng.
174. Martin-Granados C, Prescott AR, Van Dessel N, Van Eynde A, Arocena M, Klaska IP, et al. A role for PP1/NIPPI in steering migration of human cancer cells. *PloS one*. 2012;7(7):e40769. PubMed PMID: 22815811. Pubmed Central PMCID: 3397927. Epub 2012/07/21. eng.
175. Zeng Q, Huang Y, Zeng L, Cai D, Zhang H. IPP5, a novel inhibitor of protein phosphatase 1, suppresses tumor growth and progression of cervical carcinoma cells by inducing G2/M arrest. *Cancer Genet*. 2012 Sep;205(9):442-52. PubMed PMID: 22939397. Epub 2012/09/04. eng.

176. Harima Y, Ikeda K, Utsunomiya K, Shiga T, Komemushi A, Kojima H, et al. Identification of genes associated with progression and metastasis of advanced cervical cancers after radiotherapy by cDNA microarray analysis. *Int J Radiat Oncol Biol Phys*. 2009 Nov 15;75(4):1232-9. PubMed PMID: 19857786. Epub 2009/10/28. eng.
177. He K, He J, Wang S, Yan J. hSHIP induces S-phase arrest and growth inhibition in cervical cancer HeLa cells. *J Genet Genomics*. 2010 Apr;37(4):249-55. PubMed PMID: 20439101. Epub 2010/05/05. eng.
178. Rahmouni S, Cerignoli F, Alonso A, Tsutji T, Henkens R, Zhu C, et al. Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. *Nat Cell Biol*. 2006 May;8(5):524-31. PubMed PMID: 16604064. Epub 2006/04/11. eng.
179. Henkens R, Delvenne P, Arafa M, Moutschen M, Zeddou M, Tautz L, et al. Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. *BMC Cancer*. 2008;8:147. PubMed PMID: 18505570. Pubmed Central PMCID: 2413255. Epub 2008/05/29. eng.
180. Wu S, Vossius S, Rahmouni S, Miletic AV, Vang T, Vazquez-Rodriguez J, et al. Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells. *J Med Chem*. 2009 Nov 12;52(21):6716-23. PubMed PMID: 19888758. Pubmed Central PMCID: 2790023. Epub 2009/11/06. eng.
181. Huang CC, Wang JM, Kikkawa U, Mukai H, Shen MR, Morita I, et al. Calcineurin-mediated dephosphorylation of c-Jun Ser-243 is required for c-Jun protein stability and cell transformation. *Oncogene*. 2008 Apr 10;27(17):2422-9. PubMed PMID: 17952113. Epub 2007/10/24. eng.
182. Padma S, Sowjanya AP, Poli UR, Jain M, Rao B, Ramakrishna G. Downregulation of calcineurin activity in cervical carcinoma. *Cancer Cell Int*. 2005 Apr 1;5(1):7. PubMed PMID: 15801986. Pubmed Central PMCID: 1087859. Epub 2005/04/02. Eng.
183. Yeh LS, Hsieh YY, Chang JG, Chang WW, Chang CC, Tsai FJ. Mutation analysis of the tumor suppressor gene PPP2R1B in human cervical cancer. *Int J Gynecol Cancer*. 2007 Jul-Aug;17(4):868-71. PubMed PMID: 17343570. Epub 2007/03/09. eng.
184. Meng F, Zhao X, Zhang S. SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-beta production. *J Obstet Gynaecol Res*. 2012 Aug 13. PubMed PMID: 22889324. Epub 2012/08/15. Eng.
185. Liu J, Wang X, Zhou G, Wang H, Xiang L, Cheng Y, et al. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. *Gynecol Oncol*. 2011 Aug;122(2):430-6. PubMed PMID: 21575984. Epub 2011/05/18. eng.
186. Kurose K, Zhou XP, Araki T, Eng C. Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas. *Genes Chromosomes Cancer*. 2000 Oct;29(2):166-72. PubMed PMID: 10959096. Epub 2000/08/26. eng.
187. Hsieh SM, Maguire DJ, Lintell NA, McCabe M, Griffiths LR. PTEN and NDUFB8 aberrations in cervical cancer tissue. *Adv Exp Med Biol*. 2007;599:31-6. PubMed PMID: 17727244. Epub 2007/08/31. eng.
188. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. *Am J Pathol*. 2001 Jun;158(6):2097-106. PubMed PMID: 11395387. Pubmed Central PMCID: 1891985. Epub 2001/06/08. eng.
189. Lee S, Choi EJ, Jin C, Kim DH. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. *Gynecol Oncol*. 2005 Apr;97(1):26-34. PubMed PMID: 15790433. Epub 2005/03/26. eng.

190. Minaguchi T, Mori T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, et al. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. *Cancer Res.* 1999 Dec 15;59(24):6063-7. PubMed PMID: 10626791. Epub 2000/01/08. eng.
191. Takei Y, Saga Y, Mizukami H, Takayama T, Ohwada M, Ozawa K, et al. Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. *Mol Cancer Ther.* 2008 Mar;7(3):704-11. PubMed PMID: 18347155. Epub 2008/03/19. eng.
192. Wu H, Wang S, Weng D, Xing H, Song X, Zhu T, et al. Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene. *Cancer Lett.* 2008 Nov 28;271(2):205-14. PubMed PMID: 18662848. Epub 2008/07/30. eng.
193. Wu HJ, Hao Q, Wang K, Liu WX, Ma D. [Effects of PTEN gene on invasion and migration of ovarian cancer cell line A2780 and related mechanisms]. *Zhonghua Zhong Liu Za Zhi.* 2011 Mar;33(3):165-8. PubMed PMID: 21575512. Epub 2011/05/18. chi.
194. Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H. Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. *Oncogene.* 2012 May 17;31(20):2512-20. PubMed PMID: 21996746. Pubmed Central PMCID: 3262088. Epub 2011/10/15. eng.
195. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, et al. Prognostic role of CIP2A expression in serous ovarian cancer. *Br J Cancer.* 2011 Sep 27;105(7):989-95. PubMed PMID: 21897396. Pubmed Central PMCID: 3185957. Epub 2011/09/08. eng.
196. Sugiyama M, Imai A, Furui T, Tamaya T. Gonadotropin-releasing hormone retards doxorubicin-induced apoptosis and serine/threonine phosphatase inhibition in ovarian cancer cells. *Oncol Rep.* 2005 May;13(5):813-7. PubMed PMID: 15809743. Epub 2005/04/06. eng.
197. Imai A, Sugiyama M, Furui T, Tamaya T. Gi protein-mediated translocation of serine/threonine phosphatase to the plasma membrane and apoptosis of ovarian cancer cell in response to gonadotropin-releasing hormone antagonist cetorelix. *J Obstet Gynaecol.* 2006 Jan;26(1):37-41. PubMed PMID: 16390708. Epub 2006/01/05. eng.
198. Manzano RG, Montuenga LM, Dayton M, Dent P, Kinoshita I, Vicent S, et al. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. *Oncogene.* 2002 Jun 27;21(28):4435-47. PubMed PMID: 12080474. Epub 2002/06/25. eng.
199. Meinhold-Heerlein I, Stenner-Liewen F, Liewen H, Kitada S, Krajewska M, Krajewski S, et al. Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. *Am J Pathol.* 2001 Apr;158(4):1335-44. PubMed PMID: 11290551. Pubmed Central PMCID: 1891890. Epub 2001/04/06. eng.
200. Wang B, Zheng WG, Xin XY, Qi RY, Yu YC, Cao YX. [Combinative effects of FAP-1 antisense oligonucleotide and carboplatin on apoptosis of ovarian cancer cell SKOV3]. *Ai Zheng.* 2004 Aug;23(8):885-9. PubMed PMID: 15301708. Epub 2004/08/11. chi.
201. Broggini M, Buraggi G, Brenna A, Riva L, Codegani AM, Torri V, et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. *Anticancer Res.* 2000 Nov-Dec;20(6C):4835-40. PubMed PMID: 11205229. Epub 2001/02/24. eng.
202. Mok SC, Kwok TT, Berkowitz RS, Barrett AJ, Tsui FW. Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer. *Gynecol Oncol.* 1995 Jun;57(3):299-303. PubMed PMID: 7774833. Epub 1995/06/01. eng.
203. Ali AY, Abedini MR, Tsang BK. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. *Oncogene.* 2012 Apr 26;31(17):2175-86. PubMed PMID: 21927021. Epub 2011/09/20. eng.

204. Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. *Clin Cancer Res.* 2009 Apr 1;15(7):2269-80. PubMed PMID: 19293255. Epub 2009/03/19. eng.
205. Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, et al. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. *J Gynecol Oncol.* 2012 Jan;23(1):35-42. PubMed PMID: 22355465. Pubmed Central PMCID: 3280065. Epub 2012/02/23. eng.
206. Olivero M, Ruggiero T, Saviozzi S, Rasola A, Coltella N, Crispi S, et al. Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin. *Mol Cancer Ther.* 2006 May;5(5):1126-35. PubMed PMID: 16731744. Epub 2006/05/30. eng.
207. Polato F, Codegani A, Fruscio R, Perego P, Mangioni C, Saha S, et al. PRL-3 phosphatase is implicated in ovarian cancer growth. *Clin Cancer Res.* 2005 Oct 1;11(19 Pt 1):6835-9. PubMed PMID: 16203771. Epub 2005/10/06. eng.
208. Ren T, Jiang B, Xing X, Dong B, Peng L, Meng L, et al. Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer. *Pathol Oncol Res.* 2009 Dec;15(4):555-60. PubMed PMID: 19247814. Epub 2009/02/28. eng.
209. Peng L, Jin G, Wang L, Guo J, Meng L, Shou C. Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3. *Biochem Biophys Res Commun.* 2006 Mar 31;342(1):179-83. PubMed PMID: 16472776. Epub 2006/02/14. eng.
210. Guo K, Tang JP, Tan CP, Wang H, Zeng Q. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. *Cancer Biol Ther.* 2008 May;7(5):750-7. PubMed PMID: 18364570. Epub 2008/03/28. eng.
211. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, et al. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. *Clin Cancer Res.* 2003 Sep 1;9(10 Pt 1):3534-45. PubMed PMID: 14506139. Epub 2003/09/25. eng.
212. Omerovic J, Clague MJ, Prior IA. Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells. *Biochem J.* 2010 Feb 15;426(1):65-72. PubMed PMID: 19922411. Pubmed Central PMCID: 3351670. Epub 2009/11/20. eng.
213. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. *Hum Pathol.* 2005 Jul;36(7):768-76. PubMed PMID: 16084946. Epub 2005/08/09. eng.
214. Scrima M, De Marco C, De Vita F, Fabiani F, Franco R, Pirozzi G, et al. The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer. *Am J Pathol.* 2012 Mar;180(3):1202-14. PubMed PMID: 22245727. Epub 2012/01/17. eng.
215. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A, Fontanini G. CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma. *Hum Pathol.* 2007 Oct;38(10):1563-8. PubMed PMID: 17651784. Epub 2007/07/27. eng.
216. Moncho-Amor V, Ibanez de Caceres I, Bandres E, Martinez-Poveda B, Orgaz JL, Sanchez-Perez I, et al. DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. *Oncogene.* 2011 Feb 10;30(6):668-78. PubMed PMID: 20890299. Epub 2010/10/05. eng.
217. Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. *Oncogene.* 2009 Aug 6;28(31):2773-83. PubMed PMID: 19525976. Pubmed Central PMCID: 2722688. Epub 2009/06/16. eng.

218. Zheng Y, Yang W, Xia Y, Hawke D, Liu DX, Lu Z. Ras-induced and extracellular signal-regulated kinase 1 and 2 phosphorylation-dependent isomerization of protein tyrosine phosphatase (PTP)-PEST by PIN1 promotes FAK dephosphorylation by PTP-PEST. *Mol Cell Biol.* 2011 Nov;31(21):4258-69. PubMed PMID: 21876001. Pubmed Central PMCID: 3209333. Epub 2011/08/31. eng.
219. Zhai YF, Beittenmiller H, Wang B, Gould MN, Oakley C, Esselman WJ, et al. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. *Cancer Res.* 1993 May 15;53(10 Suppl):2272-8. PubMed PMID: 8097963. Epub 1993/05/15. eng.
220. Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD, Berchuck A, et al. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. *J Natl Cancer Inst.* 1994 Mar 2;86(5):372-8. PubMed PMID: 7905928. Epub 1994/03/02. eng.
221. Bentires-Alj M, Neel BG. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. *Cancer Res.* 2007 Mar 15;67(6):2420-4. PubMed PMID: 17347513. Epub 2007/03/10. eng.
222. Julien SG, Dube N, Read M, Penney J, Paquet M, Han Y, et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. *Nat Genet.* 2007 Mar;39(3):338-46. PubMed PMID: 17259984. Epub 2007/01/30. eng.
223. Balavenkatraman KK, Aceto N, Britschgi A, Mueller U, Bence KK, Neel BG, et al. Epithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance. *Mol Cancer Res.* 2011 Oct;9(10):1377-84. PubMed PMID: 21849469. Epub 2011/08/19. eng.
224. Glondou-Lassis M, Dromard M, Lacroix-Triki M, Nirde P, Puech C, Knani D, et al. PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. *Cancer Res.* 2010 Jun 15;70(12):5116-26. PubMed PMID: 20501847. Pubmed Central PMCID: 3132424. Epub 2010/05/27. eng.
225. Revillion F, Puech C, Rabenoelina F, Chalbos D, Peyrat JP, Freiss G. Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. *Int J Cancer.* 2009 Feb 1;124(3):638-43. PubMed PMID: 19004008. Pubmed Central PMCID: 2740876. Epub 2008/11/13. eng.
226. Bompard G, Puech C, Prebois C, Vignon F, Freiss G. Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells. *J Biol Chem.* 2002 Dec 6;277(49):47861-9. PubMed PMID: 12354757. Epub 2002/10/02. eng.
227. Dromard M, Bompard G, Glondou-Lassis M, Puech C, Chalbos D, Freiss G. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. *Cancer Res.* 2007 Jul 15;67(14):6806-13. PubMed PMID: 17638892. Epub 2007/07/20. eng.
228. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. *Biochem Biophys Res Commun.* 2006 Mar 3;341(1):73-81. PubMed PMID: 16412380. Epub 2006/01/18. eng.
229. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. *Breast Cancer Res Treat.* 2012 Apr;132(2):391-409. PubMed PMID: 21509526. Epub 2011/04/22. eng.
230. Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jorda M, et al. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. *Breast Cancer Res Treat.* 2011 Jul;128(1):69-78. PubMed PMID: 20669046. Epub 2010/07/30. eng.

231. Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. *Breast Cancer Res Treat.* 2012 Feb;132(1):29-39. PubMed PMID: 21512767. Epub 2011/04/23. eng.
232. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. *Mol Cancer Ther.* 2011 Jun;10(6):1093-101. PubMed PMID: 21490305. Pubmed Central PMCID: 3112276. Epub 2011/04/15. eng.
233. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. *Nat Rev Mol Cell Biol.* 2012 May;13(5):283-96. PubMed PMID: 22473468. Epub 2012/04/05. eng.
234. Miller TW, Perez-Torres M, Narasanna A, Guix M, Stal O, Perez-Tenorio G, et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. *Cancer Res.* 2009 May 15;69(10):4192-201. PubMed PMID: 19435893. Pubmed Central PMCID: 2724871. Epub 2009/05/14. eng.
235. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, et al. Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer. *Clin Cancer Res.* 2012 Aug 29. PubMed PMID: 22932669. Epub 2012/08/31. Eng.
236. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. *Cell.* 2011 Mar 4;144(5):703-18. PubMed PMID: 21376233. Epub 2011/03/08. eng.
237. Su F, Ren F, Rong Y, Wang Y, Geng Y, Feng M, et al. Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. *Breast Cancer Res.* 2012;14(2):R38. PubMed PMID: 22394684. Pubmed Central PMCID: 3446372. Epub 2012/03/08. eng.
238. Yuan T, Wang Y, Zhao ZJ, Gu H. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. *J Biol Chem.* 2010 May 14;285(20):14861-70. PubMed PMID: 20335174. Pubmed Central PMCID: 2865303. Epub 2010/03/26. eng.
239. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. *Cancer Lett.* 2003 Mar 10;191(2):229-37. PubMed PMID: 12618338. Epub 2003/03/06. eng.
240. Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. *Cancer Res.* 2007 May 1;67(9):4459-66. PubMed PMID: 17483361. Epub 2007/05/08. eng.
241. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bholra NE, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. *Nat Med.* 2012 Jul;18(7):1052-9. PubMed PMID: 22683778. Epub 2012/06/12. eng.
242. Nunes-Xavier CE, Tarrega C, Cejudo-Marin R, Frijhoff J, Sandin A, Ostman A, et al. Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester. *J Biol Chem.* 2010 Aug 20;285(34):26417-30. PubMed PMID: 20554528. Pubmed Central PMCID: 2924073. Epub 2010/06/18. eng.
243. Tang JP, Tan CP, Li J, Siddique MM, Guo K, Chan SW, et al. VHZ is a novel centrosomal phosphatase associated with cell growth and human primary cancers. *Mol Cancer.* 2010;9:128. PubMed PMID: 20509867. Pubmed Central PMCID: 2893100. Epub 2010/06/01. eng.

244. Bonin S, Brunetti D, Benedetti E, Gorji N, Stanta G. Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer. *Virchows Arch.* 2006 May;448(5):539-44. PubMed PMID: 16440198. Epub 2006/01/28. eng.
245. Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G, Jr., Ranashinge M, et al. Role of the Cdc25A phosphatase in human breast cancer. *J Clin Invest.* 2000 Sep;106(6):753-61. PubMed PMID: 10995786. Pubmed Central PMCID: 381390. Epub 2000/09/21. eng.
246. Mehdipour P, Pirouzpanah S, Sarafnejad A, Atri M, Shahrestani ST, Haidari M. Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients. *Cell Biol Int.* 2009 Oct;33(10):1050-6. PubMed PMID: 19555767. Epub 2009/06/27. eng.
247. Karagoz ID, Ozaslan M, Cengiz B, Kalender ME, Kilic IH, Oztuzcu S, et al. CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma. *Tumour Biol.* 2010 Dec;31(6):597-604. PubMed PMID: 20614206. Epub 2010/07/09. eng.
248. Feng X, Wu Z, Wu Y, Hankey W, Prior TW, Li L, et al. Cdc25A regulates matrix metalloprotease 1 through Foxo1 and mediates metastasis of breast cancer cells. *Mol Cell Biol.* 2011 Aug;31(16):3457-71. PubMed PMID: 21670150. Pubmed Central PMCID: 3147788. Epub 2011/06/15. eng.
249. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, et al. CDC25 phosphatases as potential human oncogenes. *Science.* 1995 Sep 15;269(5230):1575-7. PubMed PMID: 7667636. Epub 1995/09/15. eng.
250. Ito Y, Yoshida H, Uruno T, Takamura Y, Miya A, Kuma K, et al. Expression of cdc25A and cdc25B phosphatase in breast carcinoma. *Breast Cancer.* 2004;11(3):295-300. PubMed PMID: 15550849. Epub 2004/11/20. eng.
251. Albert H, Battaglia E, Monteiro C, Bagrel D. Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines. *Mol Oncol.* 2012 Oct;6(5):542-52. PubMed PMID: 22871320. Epub 2012/08/09. eng.
252. Albert H, Santos S, Battaglia E, Brito M, Monteiro C, Bagrel D. Differential expression of CDC25 phosphatases splice variants in human breast cancer cells. *Clin Chem Lab Med.* 2011 Oct;49(10):1707-14. PubMed PMID: 21675940. Epub 2011/06/17. eng.
253. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. *Science.* 1997 Aug 15;277(5328):965-8. PubMed PMID: 9252329. Epub 1997/08/15. eng.
254. Li C, Liang YY, Feng XH, Tsai SY, Tsai MJ, O'Malley BW. Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover. *Mol Cell.* 2008 Sep 26;31(6):835-49. PubMed PMID: 18922467. Pubmed Central PMCID: 2597059. Epub 2008/10/17. eng.
255. Wong LL, Zhang D, Chang CF, Koay ES. Silencing of the PP2A catalytic subunit causes HER-2/neu positive breast cancer cells to undergo apoptosis. *Exp Cell Res.* 2010 Dec 10;316(20):3387-96. PubMed PMID: 20558158. Epub 2010/06/19. eng.
256. Wong LL, Chang CF, Koay ES, Zhang D. Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression. *Int J Oncol.* 2009 May;34(5):1291-301. PubMed PMID: 19360341. Epub 2009/04/11. eng.
257. Kong W, Jiang X, Mercer WE. Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax. *Cancer Biol Ther.* 2009 Mar 15;8(6):555-63. PubMed PMID: 19242108. Epub 2009/02/27. eng.
258. Pandey RN, Rani R, Yeo EJ, Spencer M, Hu S, Lang RA, et al. The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. *Oncogene.* 2010 Jun 24;29(25):3715-22. PubMed PMID: 20418914. Pubmed Central PMCID: 2892025. Epub 2010/04/27. eng.

259. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties. *Oncogene*. 2012 Feb 2;31(5):552-62. PubMed PMID: 21706047. Pubmed Central PMCID: 3183358. Epub 2011/06/28. eng.
260. Krueger AB, Dehdashti SJ, Southall N, Marugan JJ, Ferrer M, Li X, et al. Identification of a Selective Small-Molecule Inhibitor Series Targeting the Eyes Absent 2 (Eya2) Phosphatase Activity. *J Biomol Screen*. 2012 Jul 20. PubMed PMID: 22820394. Epub 2012/07/24. Eng.
261. Shor AC, Agresta SV, D'Amato GZ, Sondak VK. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. *Cancer Control*. 2008 Jan;15(1):47-54. PubMed PMID: 18094660. Epub 2007/12/21. eng.
262. Shamay M, Liu J, Li R, Liao G, Shen L, Greenway M, et al. A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening. *J Virol*. 2012 May;86(9):5179-91. PubMed PMID: 22379092. Pubmed Central PMCID: 3347335. Epub 2012/03/02. eng.
263. Roy D, Dittmer DP. Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. *Am J Pathol*. 2011 Oct;179(4):2108-19. PubMed PMID: 21819957. Pubmed Central PMCID: 3181371. Epub 2011/08/09. eng.
264. Amant F, de la Rey M, Dorfling CM, van der Walt L, Dreyer G, Dreyer L, et al. PTEN mutations in uterine sarcomas. *Gynecol Oncol*. 2002 Apr;85(1):165-9. PubMed PMID: 11925138. Epub 2002/04/02. eng.
265. Grossmann AH, Layfield LJ, Randall RL. Classification, molecular characterization, and the significance of pten alteration in leiomyosarcoma. *Sarcoma*. 2012;2012:380896. PubMed PMID: 22448121. Pubmed Central PMCID: 3289834. Epub 2012/03/27. eng.
266. Kawaguchi K, Oda Y, Saito T, Takahira T, Yamamoto H, Tamiya S, et al. Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas. *Hum Pathol*. 2005 Apr;36(4):357-63. PubMed PMID: 15891996. Epub 2005/05/14. eng.
267. Bakken T, He M, Cannon ML. The phosphatase Shp2 is required for signaling by the Kaposi's sarcoma-associated herpesvirus viral GPCR in primary endothelial cells. *Virology*. 2010 Feb 20;397(2):379-88. PubMed PMID: 20004456. Pubmed Central PMCID: 2822116. Epub 2009/12/17. eng.
268. Philpott N, Bakken T, Pennell C, Chen L, Wu J, Cannon M. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor contains an immunoreceptor tyrosine-based inhibitory motif that activates Shp2. *J Virol*. 2011 Jan;85(2):1140-4. PubMed PMID: 21047965. Pubmed Central PMCID: 3020031. Epub 2010/11/05. eng.
269. Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. *Oncogene*. 2005 Apr 14;24(16):2715-22. PubMed PMID: 15782144. Epub 2005/03/23. eng.
270. Siligan C, Ban J, Bachmaier R, Spahn L, Kreppel M, Schaefer KL, et al. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. *Oncogene*. 2005 Apr 7;24(15):2512-24. PubMed PMID: 15735734. Epub 2005/03/01. eng.
271. Wang J, Chen X, Liu B, Zhu Z. Suppression of PTP1B in gastric cancer cells in vitro induces a change in the genome-wide expression profile and inhibits gastric cancer cell growth. *Cell Biol Int*. 2010 Jul;34(7):747-53. PubMed PMID: 20388125. Epub 2010/04/15. eng.
272. Loda M, Capodiceci P, Mishra R, Yao H, Corless C, Grigioni W, et al. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. *Am J Pathol*. 1996;149(5):1553-64.